Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.7.12.2 - mitogen-activated protein kinase kinase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Achondroplasia
C-type natriuretic Peptide plasma levels are elevated in subjects with achondroplasia, hypochondroplasia, and thanatophoric dysplasia.
Acidosis
Acidosis Promotes Bcl-2 Family-mediated Evasion of Apoptosis: INVOLVEMENT OF ACID-SENSING G PROTEIN-COUPLED RECEPTOR GPR65 SIGNALING TO MEK/ERK.
Acneiform Eruptions
A retrospective chart review on oral retinoids as a treatment for epidermal growth factor receptor inhibitor- and mitogen-activated protein kinase kinase inhibitor-induced acneiform eruptions.
Acute Kidney Injury
MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis.
Acute Lung Injury
Discovery of pan-ErbB inhibitors protecting from SARS-CoV-2 replication, inflammation, and lung injury by a drug repurposing screen.
Protective effects of luteolin against lipopolysaccharide-induced acute lung injury involves inhibition of MEK/ERK and PI3K/Akt pathways in neutrophils.
Adenocarcinoma
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
BKCa participates in E2 inducing endometrial adenocarcinoma by activating MEK/ERK pathway.
Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions.
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Effects of 3-Tetrazolyl Methyl-3-Hydroxy-Oxindole Hybrid (THOH) on Cell Proliferation, Apoptosis, and G2/M Cell Cycle Arrest Occurs by Targeting Platelet-Derived Growth Factor D (PDGF-D) and the MEK/ERK Signaling Pathway in Human Lung Cell Lines SK-LU-1, A549, and A-427.
Expression of EGFR, HER2, Phosphorylated ERK and Phosphorylated MEK in Colonic Neoplasms of Familial Adenomatous Polyposis Patients.
Extracellular regulated kinase (ERK)-dependent regulation of sialomucin complex/rat Muc4 in mammary epithelial cells.
HAVCR1 Affects the MEK/ERK Pathway in Gastric Adenocarcinomas and Influences Tumor Progression and Patient Outcome.
Mammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes.
miR-141 promotes colon cancer cell proliferation by inhibiting MAP2K4.
Adenocarcinoma of Lung
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.
Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression.
Downregulation of estrogen receptor ? inhibits lung adenocarcinoma cell growth.
Hit identification of SMYD3 enzyme inhibitors using structure-based pharmacophore modeling.
Hypoxic tumor-derived exosomal miR-31-5p promotes lung adenocarcinoma metastasis by negatively regulating SATB2-reversed EMT and activating MEK/ERK signaling.
KCNN4 promotes the progression of lung adenocarcinoma by activating the AKT and ERK signaling pathways.
Luteolin exerts pro-apoptotic effect and anti-migration effects on A549 lung adenocarcinoma cells through the activation of MEK/ERK signaling pathway.
Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor ?2 expression.
Olean-28,13b-olide 2 plays a role in cisplatin-mediated apoptosis and reverses cisplatin resistance in human lung cancer through multiple signaling pathways.
Adenoma
Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(?716) mice involves stromal COX-2.
Expression of EGFR, HER2, Phosphorylated ERK and Phosphorylated MEK in Colonic Neoplasms of Familial Adenomatous Polyposis Patients.
Lipopolysaccharides Enhance Epithelial Hyperplasia and Tubular Adenoma in Intestine-Specific Expression of krasV12 in Transgenic Zebrafish.
STRAP is a Critical Mediator of APC Mutation-Induced Intestinal Tumorigenesis through a Feed-Forward Mechanism.
Whole-exome sequencing identified mutational profiles of high-grade colon adenomas.
Adenomatous Polyposis Coli
Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(?716) mice involves stromal COX-2.
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Albuminuria
Inhibition of the ERK1/2-mTORC1 axis ameliorates proteinuria and the fibrogenic action of transforming growth factor-? in Adriamycin-induced glomerulosclerosis.
Alzheimer Disease
An early dysregulation of FAK and MEK/ERK signaling pathways precedes the ?-amyloid deposition in the olfactory bulb of APP/PS1 mouse model of Alzheimer's disease.
Associations of MAP2K3 Gene Variants With Superior Memory in SuperAgers.
Distribution, levels, and activation of MEK1 in Alzheimer's disease.
Increased expression and subcellular translocation of the mitogen activated protein kinase kinase and mitogen-activated protein kinase in Alzheimer's disease.
amp deaminase deficiency
AMPD3 is involved in anthrax LeTx-induced macrophage cell death.
Anthrax
Anthrax lethal factor causes proteolytic inactivation of mitogen-activated protein kinase kinase.
Anthrax Lethal Toxin Increases Superoxide Production in Murine Neutrophils via Differential Effects on MAPK Signaling Pathways.
Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase.
Chemical genetic screening identifies critical pathways in anthrax lethal toxin-induced pathogenesis.
Cross-Reactivity of Anthrax and C2 Toxin: Protective Antigen Promotes the Uptake of Botulinum C2I Toxin into Human Endothelial Cells.
Detection and quantification of anthrax lethal factor in serum by mass spectrometry.
Highly predictive support vector machine (SVM) models for anthrax toxin lethal factor (LF) inhibitors.
Identification of exosite-targeting inhibitors of anthrax lethal factor by high-throughput screening.
Mitochondrial Impairment is a Critical Event in Anthrax Lethal Toxin-Induced Cytolysis of Murine Macrophages.
Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor.
Arrhythmias, Cardiac
Antiarrhythmogenic effect of reconstituted high-density lipoprotein against ischemia/reperfusion in rats.
Arthritis
High-resolution structure discloses the potential for allosteric regulation of mitogen-activated protein kinase kinase 7.
MEK/ERK pathway inhibitors as a treatment for inflammatory arthritis might result in the development of lupus: comment on the article by Thiel et al.
Mitogen-activated protein kinase kinase 3 is a pivotal pathway regulating p38 activation in inflammatory arthritis.
Molecular targets of natural health products in arthritis.
Murine Lyme arthritis development mediated by p38 mitogen-activated protein kinase activity.
Regulation of inflammatory arthritis by the upstream kinase mitogen activated protein kinase kinase 7 in the c-Jun N-Terminal kinase pathway.
Role of MAPK kinase 6 in arthritis: distinct mechanism of action in inflammation and cytokine expression.
Arthritis, Experimental
Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms.
Arthritis, Rheumatoid
Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms.
Egr-1 inhibits the expression of extracellular matrix genes in chondrocytes by TNFalpha-induced MEK/ERK signalling.
Gene-gene interaction and RNA splicing profiles of MAP2K4 gene in rheumatoid arthritis.
Regulation of c-Jun N-terminal kinase by MEKK-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis.
Ascorbic Acid Deficiency
Dietary vitamin C deficiency depresses the growth, head kidney and spleen immunity and structural integrity by regulating NF-?B, TOR, Nrf2, apoptosis and MLCK signaling in young grass carp (Ctenopharyngodon idella).
Asthma
Anti-inflammatory effects of mitogen-activated protein kinase kinase inhibitor U0126 in an asthma mouse model.
Rhinovirus-induced MMP-9 expression is dependent on Fra-1, which is modulated by formoterol and dexamethasone.
Role of miR-27a in the regulation of cellular function via the inhibition of MAP2K4 in patients with asthma.
Astrocytoma
Fragile X mental retardation protein promotes astrocytoma proliferation via the MEK/ERK signaling pathway.
Phosphatidylinositol 3'-kinase and MAPK/ERK kinase 1/2 differentially regulate expression of vascular endothelial growth factor in human malignant astrocytoma cells.
Atherosclerosis
Identification of 4-hydroxy-2-nonenal-histidine adducts that serve as ligands for human lectin-like oxidized LDL receptor-1.
Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice.
Bacterial Infections
A non-redundant role for Drosophila Mkk4 and hemipterous/Mkk7 in TAK1-mediated activation of JNK.
Anthrax toxin component, Protective Antigen, protects insects from bacterial infections.
Bone Diseases, Metabolic
Identification of Differential Genes Expression Profiles and Pathways of Bone Marrow Mesenchymal Stem Cells of Adolescent Idiopathic Scoliosis Patients by Microarray and Integrated Gene Network Analysis.
Bone Resorption
Calcium-containing crystals enhance receptor activator of nuclear factor ?B ligand/macrophage colony-stimulating factor-mediated osteoclastogenesis via extracellular-signal-regulated kinase and p38 pathways.
Brain Injuries
Enhanced expressions of microvascular smooth muscle receptors after focal cerebral ischemia occur via the MAPK MEK/ERK pathway.
Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia.
Brain Injuries, Traumatic
Activation of Sphingosine 1-Phosphate Receptor 1 Enhances Hippocampus Neurogenesis in a Rat Model of Traumatic Brain Injury: An Involvement of MEK/Erk Signaling Pathway.
Brain Ischemia
Activated mitogen-activated protein kinase kinase 7 redistributes to the cytosol and binds to Jun N-terminal kinase-interacting protein 1 involving oxidative stress during early reperfusion in rat hippocampal CA1 region.
Activation of Akt/FoxO and inactivation of MEK/ERK pathways contribute to induction of neuroprotection against transient global cerebral ischemia by delayed hypoxic postconditioning in adult rats.
Alterations in the Cerebral Microvascular Proteome Expression Profile After Transient Global Cerebral Ischemia in Rat.
Analysis of Association between MAP2K4 Gene Polymorphism rs3826392 and IL-1b Serum Level in Southern Chinese Han Ischemic Stroke Patients.
Cerebral ischemia induces microvascular pro-inflammatory cytokine expression via the MEK/ERK pathway.
Delayed activation and regulation of MKK7 in hippocampal CA1 region following global cerebral ischemia in rats.
Elevated expression of miR-302 cluster improves traumatic brain injury by inhibiting phosphorylation of connexin43 via ERK signaling.
Enhanced cerebrovascular expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 via the MEK/ERK pathway during cerebral ischemia in the rat.
Enhanced expressions of microvascular smooth muscle receptors after focal cerebral ischemia occur via the MAPK MEK/ERK pathway.
Hypoxic Preconditioning Attenuates Neuronal Cell Death by Preventing MEK/ERK Signaling Pathway Activation after Transient Global Cerebral Ischemia in Adult Rats.
Inhibition of MEK/ERK 1/2 pathway reduces pro-inflammatory cytokine interleukin-1 expression in focal cerebral ischemia.
MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia.
microRNA-21 Confers Neuroprotection Against Cerebral Ischemia-Reperfusion Injury and Alleviates Blood-Brain Barrier Disruption in Rats via the MAPK Signaling Pathway.
Neuroprotective effects of Tongxinluo on focal cerebral ischemia and reperfusion injury in rats associated with the activation of the MEK1/2/ERK1/2/p90RSK signaling pathway.
Protein phosphatase 2A-negative regulation of the protective signaling pathway of Ca2+/CaM-dependent ERK activation in cerebral ischemia.
Similar time-course of interleukin-1 beta production and extracellular-signal-regulated kinase (ERK) activation in permanent focal brain ischemic injury.
The role of tumor necrosis factor-alpha and TNF-alpha receptors in cerebral arteries following cerebral ischemia in rat.
Brain Neoplasms
Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model.
Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Induction of transforming growth factor-beta1 by basic fibroblast growth factor in rat C6 glioma cells and astrocytes is mediated by MEK/ERK signaling and AP-1 activation.
Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.
Breast Neoplasms
Activation of c-Src/HER1/STAT5b and HER1/ERK1/2 Signaling Pathways and Cell Migration by Hexachlorobenzene in MDA-MB-231 Human Breast Cancer Cell Line.
Activation of MAP kinase by muscarinic cholinergic receptors induces cell proliferation and protein synthesis in human breast cancer cells.
Alpha-eleostearic acid suppresses proliferation of MCF-7 breast cancer cells via activation of PPARgamma and inhibition of ERK 1 / 2.
Anti-proliferative actions of N'-desmethylsorafenib in human breast cancer cells.
Artemisia absinthium (AA): a novel potential complementary and alternative medicine for breast cancer.
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.
Clustering of monosialyl-Gb5 initiates downstream signalling events leading to invasion of MCF-7 breast cancer cells.
Cross-talk between Endoplasmic Reticulum (ER) Stress and the MEK/ERK Pathway Potentiates Apoptosis in Human Triple Negative Breast Carcinoma Cells: ROLE OF A DIHYDROPYRIMIDONE, NIFETEPIMINE.
Delayed activation of extracellular-signal-regulated kinase 1/2 is involved in genistein- and equol-induced cell proliferation and estrogen-receptor-alpha-mediated transcription in MCF-7 breast cancer cells.
Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells.
Dual Inhibition of Key Proliferation Signaling Pathways in Triple-Negative Breast Cancer Cells by a Novel Derivative of Taiwanin A.
Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
Epithelial mesenchymal transition and resistance in endocrine-related cancers.
FAM53A Affects Breast Cancer Cell Proliferation, Migration, and Invasion in a p53-Dependent Manner.
Fibroblast growth factor 8 induced downregulation of thrombospondin 1 is mediated by the MEK/ERK and PI3K pathways in breast cancer cells.
Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Identification and validation of genes with expression patterns inverse to multiple metastasis suppressor genes in breast cancer cell lines.
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
Induction of apoptosis in MCF-7 and MDA-MB-231 breast cancer cells by Oligonol is mediated by Bcl-2 family regulation and MEK/ERK signaling.
Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
Inhibition of extracellular signal regulated kinase (ERK) leads to apoptosis inducing factor (AIF) mediated apoptosis in epithelial breast cancer cells: the lack of effect of ERK in p53 mediated copper induced apoptosis.
Inhibition of mitogen-activated protein kinase kinase enhances apoptosis induced by arsenic trioxide in human breast cancer MCF-7 cells.
Inhibition of mitogen-activated protein kinase kinase selectively inhibits cell proliferation in human breast cancer cells displaying enhanced insulin-like growth factor I-mediated mitogen-activated protein kinase activation.
Inhibition of mitogen-activated protein kinase signaling pathway sensitizes breast cancer cells to endoplasmic reticulum stress-induced apoptosis.
Interleukin-34-CSF1R Signaling Axis Promotes Epithelial Cell Transformation and Breast Tumorigenesis.
Low molecular proanthocyanidin dietary biofactor Oligonol: Its modulation of oxidative stress, bioefficacy, neuroprotection, food application and chemoprevention potentials.
Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
MAP2K4 interacts with Vimentin to activate the PI3K/AKT pathway and promotes breast cancer pathogenesis.
MAPK kinase 3 is a tumor suppressor with reduced copy number in breast cancer.
MEK inhibition leads to lysosome-mediated Na+/I- symporter protein degradation in human breast cancer cells.
MEK inhibition prevents tumour-shed transforming growth factor-?-induced T-regulatory cell augmentation in tumour milieu.
Metalloprotease-dependent activation of EGFR modulates CD44(+)/CD24(-) populations in triple negative breast cancer cells through the MEK/ERK pathway.
Metastasis suppressor genes: basic biology and potential clinical use.
Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer.
MicroRNA-1 regulates the growth and chemosensitivity of breast cancer cells by targeting MEK/ERK pathway.
MiR-96-5p promotes breast cancer migration by activating MEK/ERK signaling.
Mitogen-activated protein kinase kinase 3 induces cell cycle arrest via p38 activation mediated Bmi-1 downregulation in hepatocellular carcinoma.
Mutation rate of MAP2K4/MKK4 in breast carcinoma.
Naturally occurring Girinimbine alkaloid inhibits the proliferation, migration, and invasion of human breast cancer cells via induction of apoptosis and inhibition of MEK/ERK and STAT3 signalling pathways.
Neddylation controls basal MKK7 kinase activity in breast cancer cells.
Oncostatin M-induced growth inhibition and morphological changes of MDA-MB231 breast cancer cells are abolished by blocking the MEK/ERK signaling pathway.
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.
p38 isoforms have opposite effects on AP-1-dependent transcription through regulation of c-Jun. The determinant roles of the isoforms in the p38 MAPK signal specificity.
PDGF regulated migration of mesenchymal stem cells towards malignancy acts via the PI3K signaling pathway.
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.
Pifithrin-?, an inhibitor of p53 transactivation, up-regulates COX-2 expression through an MAPK-dependent pathway.
Proteome profiling of immortalization-to-senescence transition of human breast epithelial cells identified MAP2K3 as a senescence-promoting protein which is downregulated in human breast cancer.
PTEN sensitizes MDA-MB-468 cells to inhibition of MEK/Erk signaling for the blockade of cell proliferation.
Retinoids interfere with the AP1 signalling pathway in human breast cancer cells.
Shionone suppresses the growth, migration and invasion of human breast cancer cells via induction of apoptosis and inhibition of MEK/ERK and STAT3 signalling pathways.
Specific amino acid deficiency alters the expression of genes in human melanoma and other tumor cell lines.
Splicing factor hnRNPA2B1 contributes to tumorigenic potential of breast cancer cells through STAT3 and ERK1/2 signaling pathway.
Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer.
The Histone Deacetylase Inhibitor JAHA Down-Regulates pERK and Global DNA Methylation in MDA-MB231 Breast Cancer Cells.
The novel long noncoding RNA AU021063, induced by IL-6/Arid5a signaling, exacerbates breast cancer invasion and metastasis by stabilizing Trib3 and activating the Mek/Erk pathway.
The requirement of SEPT2 and SEPT7 for migration and invasion in human breast cancer via MEK/ERK activation.
The synthetic ?-nitrostyrene derivative CYT-Rx20 induces breast cancer cell death and autophagy via ROS-mediated MEK/ERK pathway.
Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer.
Three-dimensional overlay culture models of human breast cancer reveal a critical sensitivity to mitogen-activated protein kinase kinase inhibitors.
Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways.
[Expressions of MAP2K4 and estrogen receptor and their clinical significance in invasive breast cancer].
Carcinogenesis
3-Nitrobenzanthrone promotes malignant transformation in human lung epithelial cells through the epiregulin-signaling pathway.
A functional variant (-1304T>G) in the MKK4 promoter contributes to a decreased risk of lung cancer by increasing the promoter activity.
Advanced pharmacological therapies for neurofibromatosis type 1-related tumors.
CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo.
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.
Detection of novel copy number variants in uterine leiomyomas using high-resolution SNP arrays.
Differential Activation of ERK Signaling in HPV-Related Oropharyngeal Squamous Cell Carcinoma.
Diverse somatic mutation patterns and pathway alterations in human cancers.
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Essential, non-redundant roles of B-Raf and Raf-1 in Ras-driven skin tumorigenesis.
Evaluation of the association between the -1304T>G polymorphism in the promoter of the MKK4 gene and the risk of colorectal cancer: a PRISMA-compliant meta-analysis.
Flavonoids as Protein Kinase Inhibitors for Cancer Chemoprevention: Direct Binding and Molecular Modeling.
Functional variant (-1304T>G) in the MKK4 promoter is associated with decreased risk of acute myeloid leukemia in a southern Chinese population.
Geldanamycin and its anti-cancer activities.
Gene expression profiles in liver of mouse after chronic exposure to drinking water.
Hematopoietic cell kinase enhances osteosarcoma development via the MEK/ERK pathway.
In vivo effect of alpha-bisabolol, a nontoxic sesquiterpene alcohol, on the induction of spontaneous mammary tumors in HER-2/neu transgenic mice.
Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells.
Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications.
Interleukin-34-CSF1R Signaling Axis Promotes Epithelial Cell Transformation and Breast Tumorigenesis.
K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling.
Lgr4 is crucial for skin carcinogenesis by regulating MEK/ERK and Wnt/?-catenin signaling pathways.
Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor ?2 expression.
MAPK7 and MAP2K4 as prognostic markers in osteosarcoma.
MEK2 is a critical modulating mechanism to down-regulate GCIP stability and function in cancer cells.
Multitargeted cancer prevention by quercetin.
Nanosized Modification Strategies for Improving the Antitumor Efficacy of MEK Inhibitors.
Novel tumor-suppressor function of KLF4 in pediatric T-cell acute lymphoblastic leukemia.
RASSF9 promotes NSCLC cell proliferation by activating the MEK/ERK axis.
REX-1 Represses RASSF1a and Activates the MEK/ERK Pathway to Promote Tumorigenesis in Prostate Cancer.
Role of erbB3 receptors in cancer therapeutic resistance.
Steady-State Levels of Phosphorylated Mitogen-Activated Protein Kinase Kinase 1/2 Determined by Mortalin/HSPA9 and Protein Phosphatase 1 Alpha in KRAS and BRAF Tumor Cells.
Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
Targets of Raf in tumorigenesis.
TGF? engages MEK/ERK to differentially regulate benign and malignant pancreas cell function.
The Association Between -1304T>G Polymorphism in the Promoter of Mitogen-Activated Protein Kinase Kinase 4 Gene and the Risk of Cervical Cancer in Chinese Population.
The DNA replication regulator MCM6: An emerging cancer biomarker and target.
The miR-19b-3p-MAP2K3-STAT3 feedback loop regulates cell proliferation and invasion in esophageal squamous cell carcinoma.
TPL2 Is an oncogenic driver in keratocanthoma and squamous cell carcinoma.
Upregulation of MEK5 by Stat3 promotes breast cancer cell invasion and metastasis.
Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.
Carcinoma
A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib.
Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.
ASK1 mediates apoptotic cell death induced by genotoxic stress.
CCNY Accelerates Cylcin E Expression to Regulate the Proliferation of Laryngeal Carcinoma Cells via MEK/ERK Signaling Pathway.
Correction: ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma.
Cyr61 promotes CD204 expression and the migration of macrophages via MEK/ERK pathway in esophageal squamous cell carcinoma.
Differential expression of phosphorylated MEK and ERK correlates with aggressive BCC subtypes.
Editorial comment on: Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.
Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion.
Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers.
Genistein inhibits the proliferation, migration and invasion of the squamous cell carcinoma cells via inhibition of MEK/ERK and JNK signalling pathways.
Inhibition of Pancreatic Carcinoma Growth Through Enhancing ?-3 Epoxy Polyunsaturated Fatty Acid Profile by Inhibition of Soluble Epoxide Hydrolase.
Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells.
Kinase domain mutation of MAP2K4 is rare in gastric, colorectal and lung carcinomas.
Mammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes.
MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
MEK1 and Erk1/2 kinases as targets for the modulation of radiation responses.
MicroRNA-802 plays a tumour suppressive role in tongue squamous cell carcinoma through directly targeting MAP2K4.
Mitogen activated protein kinase kinase kinase 3 (MAP3K3/MEKK3) overexpression is an early event in esophageal tumorigenesis and is a predictor of poor disease prognosis.
Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma.
Mutation analyses of 268 candidate genes in human tumor cell lines.
Overexpression of integrin ?v facilitates proliferation and invasion of oral squamous cell carcinoma cells via MEK/ERK signaling pathway that is activated by interaction of integrin ?v?8 with type ? collagen.
Overexpression of mitogen-activated protein kinase kinase 4 and nuclear factor-kappaB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis.
Purpurogallin is a novel mitogen-activated protein kinase kinase 1/2 inhibitor that suppresses esophageal squamous cell carcinoma growth in vitro and in vivo.
Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma.
The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment.
Upregulation of lncRNA ADAMTS9-AS2 Promotes Salivary Adenoid Cystic Carcinoma Metastasis via PI3K/Akt and MEK/Erk Signaling.
Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1.
Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.
ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma.
[Effect of enhancer of zeste homolog 2 inhibitor GSK126 on the proliferation and apoptosis of tongue squamous cell carcinoma].
[Expression of MEK/ERK signal pathways in renal cell carcinoma with bone metastasis].
[The relationship between expression of mitogen-activated protein kinase kinase 4 and metastasis in oral squamous cell carcinoma].
Carcinoma in Situ
Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E ?-tocotrienol.
Carcinoma, Adenoid Cystic
Upregulation of lncRNA ADAMTS9-AS2 Promotes Salivary Adenoid Cystic Carcinoma Metastasis via PI3K/Akt and MEK/Erk Signaling.
Carcinoma, Basal Cell
Differential expression of phosphorylated MEK and ERK correlates with aggressive BCC subtypes.
Carcinoma, Ductal
Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
Carcinoma, Hepatocellular
?-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: A novel functional target for gefitinib.
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
Autophagy-related gene 7 (Atg7) and reactive oxygen species (ROS)/ extracellular-signal-regulated kinase (ERK) regulate tetrandrine-induced autophagy in human hepatocellular carcinoma.
Cellular mechanisms of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MAPK signaling in hepatocellular carcinoma.
CircRNA CDR1as/miR-1287/Raf1 Axis Modulates Hepatocellular Carcinoma Progression Through MEK/ERK Pathway.
Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepatocellular carcinoma cells.
Effect of halofuginone on the inhibition of proliferation and invasion of hepatocellular carcinoma HepG2 cell line.
Epidermal growth factor upregulates the expression of A20 in hepatic cells via the MEK1/MSK1/p-p65 (Ser276) signaling pathway.
FAM83D activates the MEK/ERK signaling pathway and promotes cell proliferation in hepatocellular carcinoma.
HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
Inhibition of MEK/ERK activation attenuates autophagy and potentiates pemetrexed-induced activity against HepG2 hepatocellular carcinoma cells.
Insulin Dependant Gene Expression of Heat Shock Protein 60 in H4IIE Hepatoma Cells.
Interstitial Fluid Flow Increases Hepatocellular Carcinoma Cell Invasion through CXCR4/CXCL12 and MEK/ERK Signaling.
Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma.
Kinesin family member 2C promotes hepatocellular carcinoma growth and metastasis via activating MEK/ERK pathway.
LDLR inhibition promotes hepatocellular carcinoma proliferation and metastasis by elevating intracellular cholesterol synthesis through the MEK/ERK signaling pathway.
lncRNA DRHC inhibits proliferation and invasion in hepatocellular carcinoma via c-Myb-regulated MEK/ERK signaling.
LncRNA HOXA-AS3 Sponges miR-29c to Facilitate Cell Proliferation, Metastasis, and EMT Process and Activate the MEK/ERK Signaling Pathway in Hepatocellular Carcinoma.
MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.
MEK/ERK pathway is positively involved in hypoxia-induced vasculogenic mimicry formation in hepatocellular carcinoma which is regulated negatively by protein kinase A.
MEK/ERK signaling is a critical mediator for integrin-induced cell scattering in highly metastatic hepatocellular carcinoma cells.
MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells.
Mitogen-activated protein kinase kinase 3 induces cell cycle arrest via p38 activation mediated Bmi-1 downregulation in hepatocellular carcinoma.
Modulation of YrdC promotes hepatocellular carcinoma progression via MEK/ERK signaling pathway.
NO donor inhibits proliferation and induces apoptosis by targeting PI3K/AKT/mTOR and MEK/ERK pathways in hepatocellular carcinoma cells.
Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway.
Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
Recent developments with immunotherapy for hepatocellular carcinoma.
Receptor for activated C kinase 1 promotes hepatocellular carcinoma growth by enhancing mitogen-activated protein kinase kinase 7 activity.
Resistance to MEK inhibitors correlates with upregulation of the MEK/ERK pathway in hepatocellular carcinoma cells.
Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway.
SERPINA11 Inhibits Metastasis in Hepatocellular Carcinoma by Suppressing MEK/ERK Signaling Pathway.
Silencing of long noncoding RNA HOXD-AS1 inhibits proliferation, cell cycle progression, migration and invasion of hepatocellular carcinoma cells through MEK/ERK pathway.
Stereoisomeric guaiacylglycerol-?-coniferyl aldehyde ether induces distinctive apoptosis by downregulation of MEK/ERK pathway in hepatocellular carcinoma cells.
STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems.
The Activation of MEK/ERK Signaling Pathway by Bone Morphogenetic Protein 4 to Increase Hepatocellular Carcinoma Cell Proliferation and Migration.
[Cross-talk between PI3K/Akt and MEK/ERK pathways regulates human hepatocellular carcinoma cell cycle progression under endoplasmic reticulum stress].
Carcinoma, Intraductal, Noninfiltrating
Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.
Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
Carcinoma, Non-Small-Cell Lung
Aldehyde Dehydrogenase 1 (ALDH1) Promotes the Toxicity of TRAIL in Non-Small Cell Lung Cancer Cells via Post-Transcriptional Regulation of MEK-1 Expression.
Blockade of ?7 nicotinic acetylcholine receptors inhibit nicotine-induced tumor growth and vimentin expression in non-small cell lung cancer through MEK/ERK signaling way.
Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Combination therapies with mitogen-activated protein kinase kinase inhibitors and immune checkpoint inhibitors in non-small cell lung cancer.
Concurrent inhibition of ErbB family and MEK/ERK kinases to suppress non-small cell lung cancer proliferation.
Enhanced G1 arrest and apoptosis via MDM4/MDM2 double knockdown and MEK inhibition in wild-type TP53 colon and gastric cancer cells with aberrant KRAS signaling.
Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells.
Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers.
Gastrointestinal perforation following dabrafenib and trametinib administration in non-small cell lung carcinoma with BRAF V600E mutation: a case report and literature review.
Gefitinib-Resistance Is Related to BIM Expression in Non-Small Cell Lung Cancer Cell Lines.
Inhibition of histamine receptor H3 suppresses the growth and metastasis of human non-small cell lung cancer cells via inhibiting PI3K/Akt/mTOR and MEK/ERK signaling pathways and blocking EMT.
KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach.
Loss of MKK3 and MK2 Copy Numbers in Non-Small Cell Lung Cancer.
MiR-199a-5p suppresses non-small cell lung cancer via targeting MAP3K11.
Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway.
PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.
Population Pharmacokinetic and Exposure-Response Analysis of Selumetinib and Its N-desmethyl Metabolite in Patients With Non-Small Cell Lung Cancer.
Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway.
The antitumor effect of hinesol, extract from Atractylodes lancea (Thunb.) DC. by proliferation, inhibition, and apoptosis induction via MEK/ERK and NF-?B pathway in non-small cell lung cancer cell lines A549 and NCI-H1299.
Carcinoma, Renal Cell
Alpha-Mangostin Suppresses the Metastasis of Human Renal Carcinoma Cells by Targeting MEK/ERK Expression and MMP-9 Transcription Activity.
Aqueous Extracts of Toona sinensis Leaves Inhibit Renal Carcinoma Cell Growth and Migration Through JAK2/stat3, Akt, MEK/ERK, and mTOR/HIF-2? Pathways.
Correction: ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma.
Editorial comment on: Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.
Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.
ZHX2 drives cell growth and migration via activating MEK/ERK signal and induces Sunitinib resistance by regulating the autophagy in clear cell Renal Cell Carcinoma.
[Expression of MEK/ERK signal pathways in renal cell carcinoma with bone metastasis].
Carcinoma, Squamous Cell
Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion.
Genistein inhibits the proliferation, migration and invasion of the squamous cell carcinoma cells via inhibition of MEK/ERK and JNK signalling pathways.
MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
MicroRNA-802 plays a tumour suppressive role in tongue squamous cell carcinoma through directly targeting MAP2K4.
Migration induced by epidermal and hepatocyte growth factors in oral squamous carcinoma cells in vitro: role of MEK/ERK, p38 and PI-3 kinase/Akt.
Retracted: Xanthoxyletin Inhibits Proliferation of Human Oral Squamous Carcinoma Cells and Induces Apoptosis, Autophagy, and Cell Cycle Arrest by Modulation of the MEK/ERK Signaling Pathway.
Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1.
Xanthoxyletin Inhibits Proliferation of Human Oral Squamous Carcinoma Cells and Induces Apoptosis, Autophagy, and Cell Cycle Arrest by Modulation of the MEK/ERK Signaling Pathway.
[Effect of enhancer of zeste homolog 2 inhibitor GSK126 on the proliferation and apoptosis of tongue squamous cell carcinoma].
Cardiomegaly
Angiotensin II mediates mechanical stress-induced cardiac hypertrophy.
Angiotensin II-induced cardiac hypertrophy is associated with different mitogen-activated protein kinase activation in normotensive and hypertensive mice.
Angiotensin-Converting Enzyme 3 (ACE3) Protects Against Pressure Overload-Induced Cardiac Hypertrophy.
Baicalein protects against cardiac hypertrophy through blocking MEK-ERK1/2 signaling.
Caffeic acid phenethyl ester attenuates pathological cardiac hypertrophy by regulation of MEK/ERK signaling pathway in vivo and vitro.
Cardiac hypertrophy induced by mitogen-activated protein kinase kinase 7, a specific activator for c-Jun NH2-terminal kinase in ventricular muscle cells.
Caspase recruitment domain 6 protects against cardiac hypertrophy in response to pressure overload.
GADD45B inhibits MKK7-induced cardiac hypertrophy and the polymorphisms of GADD45B is associated with inter-ventricular septum hypertrophy.
Growth Arrest-Specific 6 Exacerbates Pressure Overload-Induced Cardiac Hypertrophy.
High-resolution structure discloses the potential for allosteric regulation of mitogen-activated protein kinase kinase 7.
Interleukin 6 is not necessary for STAT3 phosphorylation and myocardial hypertrophy following short term beta-adrenergic stimulation.
Mechanical stress activates protein kinase cascade of phosphorylation in neonatal rat cardiac myocytes.
Molecular aspects of mechanical stress-induced cardiac hypertrophy.
Opposing effects of Jun kinase and p38 mitogen-activated protein kinases on cardiomyocyte hypertrophy.
Rapamycin Inhibits Cardiac Hypertrophy by Promoting Autophagy via the MEK/ERK/Beclin-1 Pathway.
Rat parathyroid hormone 1-34 signals through the MEK/ERK pathway to induce cardiac hypertrophy.
Zebrafish heart failure models for the evaluation of chemical probes and drugs.
[Parathyroid hormone 1-34 induce cardiac myocytes hypertrophy via extracellular regulated protein kinase 1/2 pathway]
Cardiomyopathies
Mitogen-activated protein kinase kinase 1/2 inhibition and angiotensin II converting inhibition in mice with cardiomyopathy caused by lamin A/C gene mutation.
Type 5 Adenylyl Cyclase Increases Oxidative Stress by Transcriptional Regulation of MnSOD via the SIRT1/FoxO3a Pathway.
Cardiomyopathy, Hypertrophic
Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.
Cardiotoxicity
Ageing alters the severity of Sunitinib-induced cardiotoxicity: Investigating the mitogen activated kinase kinase 7 pathway association.
Involvement of mitogen activated kinase kinase 7 intracellular signalling pathway in Sunitinib-induced cardiotoxicity.
The epigallocatechin gallate derivative Y6 reduces the cardiotoxicity and enhances the efficacy of daunorubicin against human hepatocellular carcinoma by inhibiting carbonyl reductase 1 expression.
Vincristine attenuates doxorubicin cardiotoxicity.
Cell Transformation, Neoplastic
Cocoa procyanidins suppress transformation by inhibiting mitogen-activated protein kinase kinase.
Central Serous Chorioretinopathy
Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy.
Cerebral Infarction
microRNA-21 Confers Neuroprotection Against Cerebral Ischemia-Reperfusion Injury and Alleviates Blood-Brain Barrier Disruption in Rats via the MAPK Signaling Pathway.
PI3K/Akt and ERK1/2 pathways are responsible for sodium butyrateinduced inhibition of neuronal apoptosis in rats with cerebral infarction.
Cholangiocarcinoma
MiR-192-5p regulates the proliferation and apoptosis of cholangiocarcinoma cells by activating MEK/ERK pathway.
Cholera
Dual regulation of intermediate filament phosphorylation.
Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells.
Chondrosarcoma
Glial cell-derived neurotrophic factor increases migration of human chondrosarcoma cells via ERK and NF-kappaB pathways.
Involvement of integrin up-regulation in RANKL/RANK pathway of chondrosarcomas migration.
SDF-1/CXCR4 signaling up-regulates survivin to regulate human sacral chondrosarcoma cell cycle and epithelial-mesenchymal transition via ERK and PI3K/AKT pathway.
TGF-beta-induced expression of tissue inhibitor of metalloproteinases-3 gene in chondrocytes is mediated by extracellular signal-regulated kinase pathway and Sp1 transcription factor.
Chordoma
The FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth and survival.
Choriocarcinoma
Neutral endopeptidase/CD10 expression during phorbol ester-induced differentiation of choriocarcinoma cells through the protein kinase C- and extracellular signal-regulated kinase-dependent signalling pathway.
Choroidal Neovascularization
Role of PI3K/Akt and MEK/ERK in mediating hypoxia-induced expression of HIF-1alpha and VEGF in laser-induced rat choroidal neovascularization.
Classical Swine Fever
Mitogen-activated Protein Kinase Kinase 2 (MEK2), a Novel E2-interacting Protein, Promotes the Growth of Classical Swine Fever Virus via Attenuation of the JAK-STAT Signaling Pathway.
Coinfection
Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling.
Colitis
Dietary oligosaccharides attenuate DSS-induced colitis in mice, induce PGlyRP3 expression, and inhibit NF-?B and MEK/ERK signaling.
Raf protects against colitis by promoting mouse colon epithelial cell survival through NF-kappaB.
Randomised clinical trial: Efficacy and safety of Qing-Chang-Hua-Shi granules in a multicenter, randomized, and double-blind clinical trial of patients with moderately active ulcerative colitis.
Retraction notice to "Dietary oligosaccharides attenuate DSS-induced colitis in mice, induce PGlyRP3 expression, and inhibit NF-?B and MEK/ERK signaling" [Cell. Immunol. 354 (2020) 104144].
SGK1 inhibits cellular apoptosis and promotes proliferation via the MEK/ERK/p53 pathway in colitis.
Colitis, Ulcerative
Qing Chang Hua Shi granule ameliorate inflammation in experimental rats and cell model of ulcerative colitis through MEK/ERK signaling pathway.
Colonic Neoplasms
Activation of ERK signaling and induction of colon cancer cell death by piperlongumine.
Activin and TGF? use diverging mitogenic signaling in advanced colon cancer.
Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(?716) mice involves stromal COX-2.
Berbamine exerts anticancer effects on human colon cancer cells via induction of autophagy and apoptosis, inhibition of cell migration and MEK/ERK signalling pathway.
Ca(2+)/calmodulin-dependent protein kinase II promotes cell cycle progression by directly activating MEK1 and subsequently modulating p27 phosphorylation.
Combination of CYP inhibitor with MEK/ERK inhibitor enhances the inhibitory effect on ERK in BRAF mutant colon cancer cells.
Dihydroartemisinin increases apoptosis of colon cancer cells through targeting Janus kinase 2/signal transducer and activator of transcription 3 signaling.
FABP7 promotes cell proliferation and survival in colon cancer through MEK/ERK signaling pathway.
Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites.
Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites.
MAP kinase genes and colon and rectal cancer.
Matrine triggers colon cancer cell apoptosis and G0/G1 cell cycle arrest via mediation of microRNA-22.
MEK Inhibitor Suppresses Expression of the miR-17-92 Cluster with G1-Phase Arrest in HT-29 Human Colon Cancer Cells and MIA PaCa-2 Pancreatic Cancer Cells.
MicroRNA-335 targets the MEK/ERK pathway to regulate the proliferation and metastasis of colon cancer.
miR-141 promotes colon cancer cell proliferation by inhibiting MAP2K4.
Oncogenic Ras upregulates NADPH oxidase 1 gene expression through MEK-ERK-dependent phosphorylation of GATA-6.
Quantitative Size-Based Analysis of Tumor Spheroids and Responses to Therapeutics.
The molecular chaperone Cosmc enhances malignant behaviors of colon cancer cells via activation of Akt and ERK.
Verticillin A increases the BIMEL/MCL-1 ratio to overcome ABT-737-resistance in human colon cancer cells by targeting the MEK/ERK pathway.
Xanthohumol chalcone acts as a powerful inhibitor of carcinogenesis in drug-resistant human colon carcinoma and these effects are mediated via G2/M phase cell cycle arrest, activation of apoptotic pathways, caspase activation and targeting Ras /MEK/ERK pathway.
Colorectal Neoplasms
Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells.
Cetuximab improves AZD6244 antitumor activity in colorectal cancer HT29 cells in vitro and in nude mice by attenuating HER3/Akt pathway activation.
Combination of CYP inhibitor with MEK/ERK inhibitor enhances the inhibitory effect on ERK in BRAF mutant colon cancer cells.
Development and External Validation of a Novel Immune Checkpoint-Related Gene Signature for Prediction of Overall Survival in Hepatocellular Carcinoma.
Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib.
HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway.
Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells.
Inducing effects of hepatocyte growth factor on the expression of vascular endothelial growth factor in human colorectal carcinoma cells through MEK and PI3K signaling pathways.
Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites.
Inhibition of MEK sensitizes paclitaxel-induced apoptosis of human colorectal cancer cells by downregulation of GRP78.
km23-1/DYNLRB1 regulation of MEK/ERK signaling and R-Ras in invasive human colorectal cancer cells.
LIM and SH3 protein 1 knockdown suppresses proliferation and metastasis of colorectal carcinoma cells via inhibition of the mitogen-activated protein kinase signaling pathway.
MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines.
Nanocomplexes loaded with miR-128-3p for enhancing chemotherapy effect of colorectal cancer through dual-targeting silence the activity of PI3K/AKT and MEK/ERK pathway.
Oncogenic K-ras activates p38 to maintain colorectal cancer cell proliferation during MEK inhibition.
PAR4 overexpression promotes colorectal cancer cell proliferation and migration.
Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Resistance to 3-HTMC-induced apoptosis through activation of PI3K/Akt, MEK/ERK and p38/COX-2/PGE2 pathways in human HT-29 and HCT116 colorectal cancer cells.
Silencing of linc00337 inhibits proliferation, cell cycle progression, migration, and invasion of colorectal cancer cells through the MEK/ERK pathway.
Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells.
Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells.
The molecular chaperone Cosmc enhances malignant behaviors of colon cancer cells via activation of Akt and ERK.
The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism.
The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent.
Coronary Occlusion
AMPK is critical for mitochondrial function during reperfusion after myocardial ischemia.
Costello Syndrome
Retinoblastoma protein modulates the inverse relationship between cellular proliferation and elastogenesis.
Cysts
?-catenin ablation exacerbates polycystic kidney disease progression.
Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys.
ERK regulates renal cell proliferation and renal cyst expansion in inv mutant mice.
Hyperactivity of Mek in TNS1 knockouts leads to potential treatments for cystic kidney diseases.
Dehydration
Rice calcium/calmodulin-dependent protein kinase directly phosphorylates a mitogen-activated protein kinase kinase to regulate abscisic acid responses.
Wwox Deficiency Causes Downregulation of Prosurvival ERK Signaling and Abnormal Homeostatic Responses in Mouse Skin.
Dengue
HELZ2 Is an IFN Effector Mediating Suppression of Dengue Virus.
The dengue virus envelope protein induced PAI-1 gene expression via MEK/ERK pathways.
Diabetes Mellitus
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Injury-induced activation of ERK 1/2 in the sciatic nerve of healthy and diabetic rats.
Diabetes Mellitus, Type 1
GLP-2 restores impairments in spatial working memory and hippocampal LTD via the MEK/ERK pathway in juvenile-onset diabetes rats.
The MAPK kinase kinase-1 is essential for stress-induced pancreatic islet cell death.
Diabetes Mellitus, Type 2
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Inhibition of MEK1 Signaling Pathway in the Liver Ameliorates Insulin Resistance.
Diabetic Nephropathies
Induction of B1 receptors in streptozotocin diabetic rats: possible involvement in the control of hyperglycemia-induced glomerular Erk 1 and 2 phosphorylation.
Inhibition of IGF-I-induced Erk 1 and 2 activation and mitogenesis in mesangial cells by bradykinin.
Knock-Down of Long Non-Coding RNA ANRIL Suppresses Mouse Mesangial Cell Proliferation, Fibrosis, Inflammation via Regulating Wnt/?-Catenin and MEK/ERK Pathways in Diabetic Nephropathy.
NOD2 promotes endothelial-to-mesenchymal transition of glomerular endothelial cells via MEK/ERK signaling pathway in diabetic nephropathy.
Up-regulation of miR-20a weakens inflammation and apoptosis in high-glucose-induced renal tubular cell mediating diabetic kidney disease by repressing CXCL8 expression.
Diffuse Intrinsic Pontine Glioma
Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells.
Dwarfism
C-type natriuretic Peptide plasma levels are elevated in subjects with achondroplasia, hypochondroplasia, and thanatophoric dysplasia.
The MAP kinase MPK4 is required for cytokinesis in Arabidopsis thaliana.
Encephalitis
EP4 Receptor-Associated Protein in Microglia Promotes Inflammation in the Brain.
The small molecule AZD6244 inhibits dengue virus replication in vitro and protects against lethal challenge in a mouse model.
Encephalitis, Japanese
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Encephalitis, St. Louis
The small molecule AZD6244 inhibits dengue virus replication in vitro and protects against lethal challenge in a mouse model.
Endometrial Neoplasms
Estrogenic G protein-coupled receptor 30 signaling is involved in regulation of endometrial carcinoma by promoting proliferation, invasion potential, and interleukin-6 secretion via the MEK/ERK mitogen-activated protein kinase pathway.
Functional and Clinicopathological Analysis of Loss of MKK4 Expression in Endometrial Cancer.
Insulin promotes proliferation, survival, and invasion in endometrial carcinoma by activating the MEK/ERK pathway.
Sirtuin 2 promotes cell stemness and MEK/ERK signaling pathway while reduces chemosensitivity in endometrial cancer.
[Coexpression of MAP2K4 and vimentin proteins in human endometrial carcinoma and its clinicopathological significance].
Endometriosis
Differential expression of genes in eutopic and ectopic endometrium from patients with ovarian endometriosis.
DNA microarray analysis of gene expression profiles in deep endometriosis using laser capture microdissection.
miR-196a overexpression activates the MEK/ERK signal and represses the progesterone receptor and decidualization in eutopic endometrium from women with endometriosis.
USP10 promotes proliferation and migration and inhibits apoptosis of endometrial stromal cells in endometriosis through activating the Raf-1/MEK/ERK pathway.
Endotoxemia
Activation of extracellular signal-regulated kinases, NF-kappa B, and cyclic adenosine 5'-monophosphate response element-binding protein in lung neutrophils occurs by differing mechanisms after hemorrhage or endotoxemia.
Esophageal Neoplasms
Enhancement of peripheral benzodiazepine receptor ligand-induced apoptosis and cell cycle arrest of esophageal cancer cells by simultaneous inhibition of MAPK/ERK kinase.
Overexpression of miR-199a-5p decreases esophageal cancer cell proliferation through repression of mitogen-activated protein kinase kinase kinase-11 (MAP3K11).
PAR-2 promotes invasion and migration of esophageal cancer cells by activating MEK/ERK and PI3K/Akt signaling pathway.
Sulforaphene inhibits esophageal cancer progression via suppressing SCD and CDH3 expression, and activating the GADD45B-MAP2K3-p38-p53 feedback loop.
Up-regulation of MicroRNA-133a Inhibits the MEK/ERK Signaling Pathway to Promote Cell Apoptosis and Enhance Radio-sensitivity by targeting EGFR in Esophageal Cancer in Vivo and in Vitro.
Esophageal Squamous Cell Carcinoma
Cyr61 promotes CD204 expression and the migration of macrophages via MEK/ERK pathway in esophageal squamous cell carcinoma.
Mitogen activated protein kinase kinase kinase 3 (MAP3K3/MEKK3) overexpression is an early event in esophageal tumorigenesis and is a predictor of poor disease prognosis.
Purpurogallin is a novel mitogen-activated protein kinase kinase 1/2 inhibitor that suppresses esophageal squamous cell carcinoma growth in vitro and in vivo.
Exanthema
Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.
Fatty Liver
Activation of ERK1/2 Ameliorates Liver Steatosis in Leptin Receptor-Deficient (db/db) Mice via Stimulating ATG7-Dependent Autophagy.
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases.
Fibromatosis, Gingival
Genomic analysis of gum disease and hypertrichosis in foxes.
Fibrosarcoma
Cellular cholesterol regulates MT1 MMP dependent activation of MMP 2 via MEK-1 in HT1080 fibrosarcoma cells.
Histiocytic neoplasms in the era of personalized genomic medicine.
Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells.
Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma.
The long noncoding RNA MEG3 regulates Ras-MAPK pathway through RASA1 in trophoblast and is associated with unexplained recurrent spontaneous abortion.
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases.
TIMP-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells.
Gallbladder Neoplasms
A MEK inhibitor (U0126) markedly inhibits direct liver invasion of orthotopically inoculated human gallbladder cancer cells in nude mice.
Anti-tumor Activity of Bufalin by Inhibiting c-MET Mediated MEK/ERK and PI3K/AKT Signaling Pathways in Gallbladder Cancer.
Overexpressed microRNA-136 works as a cancer suppressor in gallbladder cancer through suppression of JNK signaling pathway via inhibition of MAP2K4.
Glioblastoma
Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model.
Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells.
FoxO3a Functions as a Key Integrator of Cellular Signals That Control Glioblastoma Stem-like Cell Differentiation and Tumorigenicity.
Histone deacetylase 1 promotes glioblastoma cell proliferation and invasion via activation of PI3K/AKT and MEK/ERK signaling pathways.
Hypoxia-induced acetylation of PAK1 enhances autophagy and promotes brain tumorigenesis via phosphorylating ATG5.
Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs.
Intronic miR-744 Inhibits Glioblastoma Migration by Functionally Antagonizing Its Host Gene MAP2K4.
Rehmannia glutinosa induces glial cell line-derived neurotrophic factor gene expression in astroglial cells via cPKC and ERK1/2 pathways independently.
Xyloketal B suppresses glioblastoma cell proliferation and migration in vitro through inhibiting TRPM7-regulated PI3K/Akt and MEK/ERK signaling pathways.
Glioma
ADAM17 promotes U87 glioblastoma stem cell migration and invasion.
Baicalein inhibits Raf-1-mediated phosphorylation of MEK-1 in C6 rat glioma cells.
Delta opioid activation of the mitogen-activated protein kinase cascade does not require transphosphorylation of receptor tyrosine kinases.
Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells.
Glial cell line-derived neurotrophic factor induces cell migration and matrix metalloproteinase-13 expression in glioma cells.
Globularifolin exerts anticancer effects on glioma U87Ā cells through inhibition of Akt/mTOR and MEK/ERK signaling pathways in vitro and inhibits tumor growth in vivo.
Hypoxia-induced acetylation of PAK1 enhances autophagy and promotes brain tumorigenesis via phosphorylating ATG5.
Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
Induction of transforming growth factor-beta1 by basic fibroblast growth factor in rat C6 glioma cells and astrocytes is mediated by MEK/ERK signaling and AP-1 activation.
Inhibition of histamine receptor 3 suppresses glioblastoma tumor growth, invasion, and epithelial-to-mesenchymal transition.
Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs.
Interaction of hsa-miR-381 and glioma suppressor LRRC4 is involved in glioma growth.
Knockdown of ER-?36 expression inhibits glioma proliferation, invasion and epithelial-to-mesenchymal transition.
Licochalcone A inhibits the invasive potential of human glioma cells by targeting the MEK/ERK and ADAM9 signaling pathways.
Long noncoding RNA HNF1A-AS1 regulates proliferation and apoptosis of glioma through activation of the JNK signaling pathway via miR-363-3p/MAP2K4.
Long noncoding RNA-GAS5 attenuates progression of glioma by eliminating microRNA-10b and Sirtuin 1 in U251 and A172 cells.
MAP-ing glioma invasion: mitogen-activated protein kinase kinase 3 and p38 drive glioma invasion and progression and predict patient survival.
MEK-ERK-dependent multiple caspase activation by mitochondrial proapoptotic Bcl-2 family proteins is essential for heavy ion irradiation-induced glioma cell death.
MEK2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment.
MicroRNA-338-5p plays a tumor suppressor role in glioma through inhibition of the MAPK-signaling pathway by binding to FOXD1.
Mitochondrial KATP Channels Control Glioma Radioresistance by Regulating ROS-Induced ERK Activation.
Protein kinase C-mediated in vitro invasion of human glioma cells through extracellular-signal-regulated kinase and ornithine decarboxylase.
Protein kinase inhibitors can suppress stress-induced dissociation of Hsp27.
Proteomic expression analysis and comparison of protein and mRNA expression profiles in human malignant gliomas.
Ro31-8220 inhibits protein kinase C to block the phorbol ester-stimulated release of choline- and ethanolamine-metabolites from C6 glioma cells: p70 S6 kinase and MAPKAP kinase-1beta do not function downstream of PKC in activating PLD.
Suppression of Rac activity induces apoptosis of human glioma cells but not normal human astrocytes.
T11TS inhibits Angiopoietin-1/Tie-2 signaling, EGFR activation and Raf/MEK/ERK pathway in brain endothelial cells restraining angiogenesis in glioma model.
The D Domain of LRRC4 anchors ERK1/2 in the cytoplasm and competitively inhibits MEK/ERK activation in glioma cells.
The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.
Transcriptional Repression of Mad-Max Complex by Human Umbilical Cord Blood Stem Cells Downregulates Extracellular Signal-Regulated Kinase in Glioblastoma.
[Mig-7 gene silencing inhibits vasculogenic mimicry formation and invasion of glioma U251 cells in vitro by suppressing MEK/ERK signaling].
[Retracted] Anticancer activity of caffeic acid n?butyl ester against A431Ā skin carcinoma cell line occurs via induction of apoptosis and inhibition of the mTOR/PI3K/AKT signaling pathway.
Glomerulonephritis, IGA
The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy.
Heart Arrest
Hypothermia and ERK activation after cardiac arrest.
Heart Defects, Congenital
Functional evidence of mTOR? splice variant involvement in the pathogenesis of congenital heart defects.
Heart Failure
Type 5 Adenylyl Cyclase Increases Oxidative Stress by Transcriptional Regulation of MnSOD via the SIRT1/FoxO3a Pathway.
Zebrafish heart failure models for the evaluation of chemical probes and drugs.
Hemangiosarcoma
Combined VEGFR and MAPK pathway inhibition in angiosarcoma.
Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells.
Hepatitis A
Knockdown of Mitogen-Activated Protein Kinase Kinase 3 Negatively Regulates Hepatitis A Virus Replication.
Hepatitis B
Hepatitis B virus core protein sensitizes hepatocytes to tumor necrosis factor-induced apoptosis by suppression of the phosphorylation of mitogen-activated protein kinase kinase 7.
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases.
Hepatitis C
Hepatitis C Virus Nonstructural 5A Protein Interacts with Abelson Interactor 1 and Modulates Epidermal Growth Factor-Mediated MEK/ERK Signaling Pathway.
Up-Regulation of Hepatitis C Virus Replication and Production by Inhibition of MEK/ERK Signaling.
Hepatoblastoma
Huaier Extract Induces Apoptosis in Hepatoblastoma Cells Via the MEK/ERK Signaling Pathway.
Herpes Simplex
Novel Agents in the Management of Pancreatic Adenocarcinoma: Phase I Studies. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Herpes Zoster
Adrenomedullin stimulates DNA synthesis of rat adrenal zona glomerulosa cells through activation of the mitogen-activated protein kinase-dependent cascade.
Herpesviridae Infections
Modulation of Kaposi's sarcoma-associated herpesvirus infection and replication by MEK/ERK, JNK, and p38 multiple mitogen-activated protein kinase pathways during primary infection.
Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways.
Histiocytic Sarcoma
Histiocytic neoplasms in the era of personalized genomic medicine.
Histiocytosis
Histiocytic neoplasms in the era of personalized genomic medicine.
HIV Infections
Kinases: Understanding Their Role in HIV Infection.
Hodgkin Disease
B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma.
MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival.
Huntington Disease
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
Hyperalgesia
Activation of spinal ERK signaling pathway contributes to pain-related responses induced by scorpion Buthus martensi Karch venom.
Early intervention of ERK activation in the spinal cord can block initiation of peripheral nerve injury-induced neuropathic pain in rats.
ERK MAP kinase activation in spinal cord regulates phosphorylation of Cdk5 at serine 159 and contributes to peripheral inflammation induced pain/hypersensitivity.
Impaired Inflammatory Pain and Thermal Hyperalgesia in Mice Expressing Neuron-Specific Dominant Negative Mitogen Activated Protein Kinase Kinase (MEK).
Low nociceptor GRK2 prolongs prostaglandin E2 hyperalgesia via biased cAMP signaling to Epac/Rap1, protein kinase Cepsilon, and MEK/ERK.
Protease-activated receptor-2 in endosomes signals persistent pain of irritable bowel syndrome.
Rational Basis for the Use of Bergamot Essential Oil in Complementary Medicine to Treat Chronic Pain.
Second messengers mediating the expression of neuroplasticity in a model of chronic pain in the rat.
Hyperglycemia
Hepatic ERK activity plays a role in energy metabolism.
High glucose exacerbates neuroinflammation and apoptosis at the intermediate stage after post-traumatic brain injury.
Hyperglycemia acutely increases monocyte extracellular signal-regulated kinase activity in vivo in humans.
Hyperglycemia reduces nitric oxide synthase and glycogen synthase activity in endothelial cells.
Increase in cardiac M(2)-muscarinic receptor expression is regulated by GATA binding protein 4 (GATA-4) in streptozotocin-induced diabetic rats.
Hyperpigmentation
Inhibition of melanogenesis by Aster yomena callus pellet extract in melanoma cells and patients with skin pigmentation.
The Anti-Melanogenesis Effect of 3,4-Dihydroxybenzalacetone through Downregulation of Melanosome Maturation and Transportation in B16F10 and Human Epidermal Melanocytes.
Hypersensitivity
A Caenorhabditis elegans MAP kinase kinase, MEK-1, is involved in stress responses.
Activation of spinal extracellular signaling-regulated kinases by intraplantar melittin injection.
An Arabidopsis kinase cascade influences auxin-responsive cell expansion.
Crosstalk between protein kinase A and the HOG pathway under impaired biosynthesis of complex sphingolipids in budding yeast.
Dexmedetomidine Relieves Acute Inflammatory Visceral Pain in Rats through the ERK Pathway, Toll-Like Receptor Signaling, and TRPV1 Channel.
jkk-1 and mek-1 regulate body movement coordination and response to heavy metals through jnk-1 in Caenorhabditis elegans.
Hypertension
Angiotensin II activates extracellular signal-regulated kinase independently of receptor tyrosine kinases in renal smooth muscle cells: implications for blood pressure regulation.
Angiotensin II-Induced vascular remodeling and hypertension involves cathepsin L/V- MEK/ERK mediated mechanism.
Cross-talking between calcium and histamine in the expression of MAPKs in hypertensive vascular smooth muscle cells.
The promoting role of Cx43 on the proliferation and migration of arterial smooth muscle cells for angiotensin II-dependent hypertension.
TRPM7 channel inhibition exacerbates pulmonary arterial hypertension through MEK/ERK pathway.
Hypertension, Pulmonary
MAP kinase kinase kinase-2 (MEKK2) regulates hypertrophic remodeling of the right ventricle in hypoxia-induced pulmonary hypertension.
Hypertrichosis
Genomic analysis of gum disease and hypertrichosis in foxes.
Hypertrophy, Left Ventricular
A combined linkage, microarray and exome analysis suggests MAP3K11 as a candidate gene for left ventricular hypertrophy.
Hypopigmentation
Inhibition of melanogenesis by gallic acid: possible involvement of the PI3K/Akt, MEK/ERK and Wnt/?-catenin signaling pathways in B16F10 cells.
Partially purified components of Nardostachys chinensis suppress melanin synthesis through ERK and Akt signaling pathway with cAMP down-regulation in B16F10 cells.
Infarction, Middle Cerebral Artery
Similar time-course of interleukin-1 beta production and extracellular-signal-regulated kinase (ERK) activation in permanent focal brain ischemic injury.
Infections
A MAP Kinase Kinase Interacts with SymRK and Regulates Nodule Organogenesis in Lotus japonicus.
Activation of Aquaporin 5 by carcinogenic Helicobacter pylori infection promotes epithelial-mesenchymal transition via the MEK/ERK pathway.
Activation of ERK2 by respiratory syncytial virus in A549 cells is linked to the production of interleukin 8.
Activation of PI3K, Akt, and ERK during early rotavirus infection leads to V-ATPase-dependent endosomal acidification required for uncoating.
Berberine inhibits enterovirus 71 replication by downregulating the MEK/ERK signaling pathway and autophagy.
Ca(2+)-independent protein kinase C activity is required for alpha1-adrenergic-receptor-mediated regulation of ribosomal protein S6 kinases in adult cardiomyocytes.
Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family.
Cellular localization and role of kinase activity of PMK1 in Magnaporthe grisea.
Chlamydiae host cell interactions revealed using DNA microarrays.
CVB3 Nonstructural 2A Protein Modulates SREBP1a Signaling via the MEK/ERK Pathway.
Detection and quantification of anthrax lethal factor in serum by mass spectrometry.
Divergent requirements for the MAPK(ERK) signal transduction pathway during initial virus infection of quiescent primary B cells and disruption of Epstein-Barr virus latency by phorbol esters.
Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression.
Effect of Cryphonectria hypovirus 1 (CHV1) infection on Cpkk1, a mitogen-activated protein kinase kinase of the filamentous fungus Cryphonectria parasitica.
Exogenous gamma and alpha/beta interferon rescues human macrophages from cell death induced by Bacillus anthracis.
Functional Involvement of a Mitogen Activated Protein Kinase Module, OsMKK3-OsMPK7-OsWRK30 in Mediating Resistance against Xanthomonas oryzae in Rice.
Helicobacter pylori activate epidermal growth factor receptor- and phosphatidylinositol 3-OH kinase-dependent Akt and glycogen synthase kinase 3beta phosphorylation.
Helicobacter pylori induces Snail expression through ROS-mediated activation of Erk and inactivation of GSK-3? in human gastric cancer cells.
Identification of novel human kinases that suppress hepatitis C virus infection.
Induction of prostaglandin endoperoxide synthase 2 by mitogen-activated protein kinase cascades.
Investigation on the partial resistance of Cpkk2 knock out strain of Cryphonectria parasitica to Cryphonectria hypovirus 1 infection in presence of Geneticin and Geneticin resistance gene.
Isolation and expression analysis of an MAPKK gene from Fenneropenaeus chinensis in response to white spot syndrome virus infection.
JCPyV-Induced MAPK Signaling Activates Transcription Factors during Infection.
Knockdown of Mitogen-Activated Protein Kinase Kinase 3 Negatively Regulates Hepatitis A Virus Replication.
Listeria monocytogenes infection of HeLa cells results in listeriolysin O-mediated transient activation of the Raf-MEK-MAP kinase pathway.
MAPK involvement in cytokine production in response to Corynebacterium pseudotuberculosis infection.
MEK/ERK signaling pathway is required for enterovirus 71 replication in immature dendritic cells.
Modulation of Kaposi's sarcoma-associated herpesvirus infection and replication by MEK/ERK, JNK, and p38 multiple mitogen-activated protein kinase pathways during primary infection.
Murine Lyme arthritis development mediated by p38 mitogen-activated protein kinase activity.
Newcastle Disease Virus Nonstructural V Protein Upregulates SOCS3 Expression to Facilitate Viral Replication Depending on the MEK/ERK Pathway.
Phosphatidylinositol 3-Kinase/Akt and MEK/ERK Signaling Pathways Facilitate Sapovirus Trafficking and Late Endosomal Acidification for Viral Uncoating in LLC-PK Cells.
Porphyromonas gingivalis activates NF?B and MAPK pathways in human oral epithelial cells.
Productive parvovirus B19 infection of primary human erythroid progenitor cells at hypoxia is regulated by STAT5A and MEK signaling but not HIF?.
Progressive Accumulation of Activated ERK2 within Highly Stable ORF45-Containing Nuclear Complexes Promotes Lytic Gammaherpesvirus Infection.
Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways.
Shedding light on autophagy coordinating with cell wall integrity signaling to govern pathogenicity of Magnaporthe oryzae.
The effect of human herpesvirus 6B infection on the MAPK pathway.
The interplay between AraƧatuba virus and host signaling pathways: role of PI3K/Akt in viral replication.
The MAP Kinase Kinase Gene AbSte7 Regulates Multiple Aspects of Alternaria brassicicola Pathogenesis.
The protective role of microRNA-21 against coxsackievirus B3 infection through targeting the MAP2K3/P38 MAPK signaling pathway.
The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells.
The RAS/Raf1/MEK/ERK Signaling Pathway Facilitates VSV-mediated Oncolysis: Implication for the Defective Interferon Response in Cancer Cells.
Transcriptome-based analysis of mitogen-activated protein kinase cascades in the rice response to Xanthomonas oryzae infection.
Influenza, Human
Polygalasaponin F treats mice with pneumonia induced by influenza virus.
Insulin Resistance
CDK5 is a key molecule in TNF-{alpha} induced insulin resistance.
Dihydromyricetin enhances glucose uptake by inhibition of MEK/ERK pathway and consequent down-regulation of phosphorylation of PPAR? in 3T3-L1 cells.
Hepatic ERK activity plays a role in energy metabolism.
Hepatic serum- and glucocorticoid-regulated protein kinase 1 (SGK1) regulates insulin sensitivity in mice via extracellular-signal-regulated kinase 1/2 (ERK1/2).
In silico analysis of non-coding RNAs and putative target genes implicated in metabolic syndrome.
Inhibition of MEK1 Signaling Pathway in the Liver Ameliorates Insulin Resistance.
Pathways leading to phosphorylation of p450c17 and to the posttranslational regulation of androgen biosynthesis.
Phosphorylation of Beta-3 adrenergic receptor at serine 247 by ERK MAP kinase drives lipolysis in obese adipocytes.
Three mitogen-activated protein kinases inhibit insulin signaling by different mechanisms in 3T3-L1 adipocytes.
Intellectual Disability
Fragile X mental retardation protein promotes astrocytoma proliferation via the MEK/ERK signaling pathway.
Ischemic Stroke
Analysis of Association between MAP2K4 Gene Polymorphism rs3826392 and IL-1b Serum Level in Southern Chinese Han Ischemic Stroke Patients.
Keratoacanthoma
Keratoacanthoma, palmoplantar keratoderma developing in an advanced melanoma patient treated with vemurafenib regressed by blockade of mitogen-activated protein kinase kinase signaling.
Keratoderma, Palmoplantar
Keratoacanthoma, palmoplantar keratoderma developing in an advanced melanoma patient treated with vemurafenib regressed by blockade of mitogen-activated protein kinase kinase signaling.
Kidney Diseases, Cystic
Hyperactivity of Mek in TNS1 knockouts leads to potential treatments for cystic kidney diseases.
Kidney Neoplasms
Chelerythrine chloride induces apoptosis in renal cancer HEK-293 and SW-839 cell lines.
Laryngeal Neoplasms
A combined modality of carboplatin and photodynamic therapy suppresses epithelial-mesenchymal transition and matrix metalloproteinase-2 (MMP-2)/MMP-9 expression in HEp-2 human laryngeal cancer cells via ROS-mediated inhibition of MEK/ERK signalling pathway.
Anticancer Activity of Mukonal Against Human Laryngeal Cancer Cells Involves Apoptosis, Cell Cycle Arrest, and Inhibition of PI3K/AKT and MEK/ERK Signalling Pathways.
Leiomyoma
Detection of novel copy number variants in uterine leiomyomas using high-resolution SNP arrays.
Leiomyosarcoma
Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics.
Leishmaniasis, Cutaneous
Cellular and humoral responses against Leishmania virulence factors in healed Cutaneous Leishmaniasis and Mediterranean Visceral Leishmaniasis patients.
Leishmaniasis, Visceral
Cellular and humoral responses against Leishmania virulence factors in healed Cutaneous Leishmaniasis and Mediterranean Visceral Leishmaniasis patients.
Leukemia
2-Deoxy-D-glucose cooperates with arsenic trioxide to induce apoptosis in leukemia cells: involvement of IGF-1R-regulated Akt/mTOR, MEK/ERK and LKB-1/AMPK signaling pathways.
Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells.
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
AMPK activators contribute to maintain naĆÆve pluripotency in mouse embryonic stem cells.
An investigation of the MEK/ERK inhibitor U0126 in acute myeloid leukemia.
Anti-proliferative actions of N'-desmethylsorafenib in human breast cancer cells.
Bcl-2 protein inhibits bufalin-induced apoptosis through inhibition of mitogen-activated protein kinase activation in human leukemia U937 cells.
Block of C/EBP{alpha} function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.
Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene.
BRAF inhibitor therapy in HCL.
Cbl-b promotes chemotherapy-induced apoptosis in rat basophilic leukemia cells by suppressing PI3K/Akt activation and enhancing MEK/ERK activation.
Chemical Reversion of Conventional Human Pluripotent Stem Cells to a NaĆÆve-like State with Improved Multilineage Differentiation Potency.
Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571.
Derivation of Embryonic Stem Cell Lines From Parthenogenetically Developing Rat Blastocysts.
Downregulating Notch counteracts KrasG12D-induced ERK activation and oxidative phosphorylation in myeloproliferative neoplasm.
Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.
FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM.
Friedelin inhibits the growth and metastasis of human leukemia cells via modulation of MEK/ERK and PI3K/AKT signalling pathways.
GDNF-induced leukemia inhibitory factor can mediate differentiation via the MEK/ERK pathway in pheochromocytoma cells derived from nf1-heterozygous knockout mice.
HDAC3 as a molecular chaperone for shuttling phosphorylated TR2 to PML: a novel deacetylase activity-independent function of HDAC3.
HMGB1 promotes differentiation syndrome by inducing hyperinflammation via MEK/ERK signaling in acute promyelocytic leukemia cells.
IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update.
Induction of differentiation-specific miRNAs in TPA-induced myeloid leukemia cells through MEK/ERK activation.
Inhibition of the MAP2K7-JNK pathway with 5Z-7-oxozeaenol induces apoptosis in T-cell acute lymphoblastic leukemia.
Interleukin-1beta can mediate growth arrest and differentiation via the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells.
Interruption of the MEK/ERK signaling cascade promotes dihydroartemisinin-induced apoptosis in vitro and in vivo.
Involvement of protein kinase C during activation of the mitogen-activated protein kinase cascade by leukemia inhibitory factor. Evidence for participation of multiple signaling pathways.
Isoflavones regulate secretion of leukemia inhibitory factor and transforming growth factor {beta} and expression of glycodelin in human endometrial epithelial cells.
Jun N-terminal kinase pathway enhances signaling of monocytic differentiation of human leukemia cells induced by 1,25-dihydroxyvitamin D3.
Leukemia inhibitory factor activates cardiac L-Type Ca2+ channels via phosphorylation of serine 1829 in the rabbit Cav1.2 subunit.
Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent.
MEK blockade converts AML differentiating response to retinoids into extensive apoptosis.
Metformin induces differentiation in acute promyelocytic leukemia by activating the MEK/ERK signaling pathway.
MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk.
Novel tumor-suppressor function of KLF4 in pediatric T-cell acute lymphoblastic leukemia.
Pharmacologic inhibitors of extracellular signal-regulated kinase (ERKs) and c-Jun NH(2)-terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia Cells to arsenic trioxide-induced apoptosis.
RAF-1/MEK/ERK pathway regulates ATRA-induced differentiation in acute promyelocytic leukemia cells through C/EBP?, C/EBP? and PU.1.
Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition.
Renal carcinogenesis in models of diabetes in rats: metabolic changes are closely related to neoplastic development.
Reprogramming of mouse somatic cells into pluripotent stem-like cells using a combination of small molecules.
Role of growth hormone signaling pathways in the development of atherosclerosis.
Small-Molecule Induction of Canine Embryonic Stem Cells Toward NaĆÆve Pluripotency.
Sorafenib inhibited cell growth through the MEK/ERK signaling pathway in acute promyelocytic leukemia cells.
Specific inhibition of basal mitogen-activated protein kinases and phosphatidylinositol 3 kinase activities in leukemia cells: a possible therapeutic role for the kinase inhibitors.
Staurosporine enhances ATRA-induced granulocytic differentiation in human leukemia U937 cells via the MEK/ERK signaling pathway.
Synergistic Interactions between DMAG and Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitors in Bcr/abl+ Leukemia Cells Sensitive and Resistant to Imatinib Mesylate.
The combination of UCN-01 and ATRA triggers differentiation in ATRA resistant acute promyelocytic leukemia cell lines via RAF-1 independent activation of MEK/ERK.
The Current State of NaĆÆve Human Pluripotency.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogen-activated protein kinase kinase inhibitors in human leukemia cells that ectopically express Bcl-2 and Bcl-xL.
Leukemia, B-Cell
MAP3K11 is a tumor suppressor targeted by the oncomiR miR-125b in early B cells.
Leukemia, Hairy Cell
BRAF inhibitor therapy in HCL.
Leukemia, Lymphocytic, Chronic, B-Cell
Bayesian inference of MicroRNA targets from sequence and expression data.
Leukemia, Lymphoid
MEK/ERK pathway protects ionizing radiation-induced loss of mitochondrial membrane potential and cell death in lymphocytic leukemia cells.
Leukemia, Monocytic, Acute
Role of growth hormone signaling pathways in the development of atherosclerosis.
Leukemia, Myeloid
Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling.
Epicatechin and a cocoa polyphenolic extract modulate gene expression in human Caco-2 cells.
Induction of differentiation-specific miRNAs in TPA-induced myeloid leukemia cells through MEK/ERK activation.
Modulation of anthracycline-induced cytotoxicity by targeting the prenylated proteome in myeloid leukemia cells.
Leukemia, Myeloid, Acute
An investigation of the MEK/ERK inhibitor U0126 in acute myeloid leukemia.
Chidamide Inhibits Acute Myeloid Leukemia Cell Proliferation by lncRNA VPS9D1-AS1 Downregulation via MEK/ERK Signaling Pathway.
Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial.
Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1.
Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell.
MEK blockade converts AML differentiating response to retinoids into extensive apoptosis.
MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia.
Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells.
PD98059 triggers G1 arrest and apoptosis in human leukemic U937 cells through downregulation of Akt signal pathway.
Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia.
The HER2 inhibitor TAK165 Sensitizes Human Acute Myeloid Leukemia Cells to Retinoic Acid-Induced Myeloid Differentiation by activating MEK/ERK mediated RAR?/STAT1 axis.
Leukemia, Promyelocytic, Acute
HMGB1 promotes differentiation syndrome by inducing hyperinflammation via MEK/ERK signaling in acute promyelocytic leukemia cells.
Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent.
MEK blockade converts AML differentiating response to retinoids into extensive apoptosis.
Metformin induces differentiation in acute promyelocytic leukemia by activating the MEK/ERK signaling pathway.
Pharmacologic inhibitors of extracellular signal-regulated kinase (ERKs) and c-Jun NH(2)-terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia Cells to arsenic trioxide-induced apoptosis.
RAF-1/MEK/ERK pathway regulates ATRA-induced differentiation in acute promyelocytic leukemia cells through C/EBP?, C/EBP? and PU.1.
Sorafenib inhibited cell growth through the MEK/ERK signaling pathway in acute promyelocytic leukemia cells.
The combination of UCN-01 and ATRA triggers differentiation in ATRA resistant acute promyelocytic leukemia cell lines via RAF-1 independent activation of MEK/ERK.
Leukemia-Lymphoma, Adult T-Cell
Transcriptional regulation of parathyroid hormone-related protein promoter P3 by ETS-1 in adult T-cell leukemia/lymphoma.
Liver Cirrhosis
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases.
Liver Diseases
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases.
Liver Neoplasms
miR-330-3p suppresses liver cancer cell migration by targeting MAP2K1.
Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway.
RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo.
The role and mechanism of WEE1 on the cisplatin resistance reversal of the HepG2/DDP human hepatic cancer cell line.
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases.
Lung Injury
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis.
The effect of miR-21-5p on the MAP2K3 expressions and cellular apoptosis in the lung tissues of neonatal rats with hyperoxia-induced lung injuries.
Lung Neoplasms
A bombesin receptor subtype-3 peptide increases nuclear oncogene expression in a MEK-1 dependent manner in human lung cancer cells.
A Ferulic Acid Derivative FXS-3 Inhibits Proliferation and Metastasis of Human Lung Cancer A549 Cells via Positive JNK Signaling Pathway and Negative ERK/p38, AKT/mTOR and MEK/ERK Signaling Pathways.
AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model.
Aldehyde Dehydrogenase 1 (ALDH1) Promotes the Toxicity of TRAIL in Non-Small Cell Lung Cancer Cells via Post-Transcriptional Regulation of MEK-1 Expression.
An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell Through Suppressing the MEK/ERK Pathway.
Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells.
Blockade of ?7 nicotinic acetylcholine receptors inhibit nicotine-induced tumor growth and vimentin expression in non-small cell lung cancer through MEK/ERK signaling way.
Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
BYL719, a selective inhibitor of phosphoinositide 3-Kinase ?, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms.
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Combination therapies with mitogen-activated protein kinase kinase inhibitors and immune checkpoint inhibitors in non-small cell lung cancer.
Concurrent inhibition of ErbB family and MEK/ERK kinases to suppress non-small cell lung cancer proliferation.
Effects of 3-Tetrazolyl Methyl-3-Hydroxy-Oxindole Hybrid (THOH) on Cell Proliferation, Apoptosis, and G2/M Cell Cycle Arrest Occurs by Targeting Platelet-Derived Growth Factor D (PDGF-D) and the MEK/ERK Signaling Pathway in Human Lung Cell Lines SK-LU-1, A549, and A-427.
Enhanced G1 arrest and apoptosis via MDM4/MDM2 double knockdown and MEK inhibition in wild-type TP53 colon and gastric cancer cells with aberrant KRAS signaling.
Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition.
Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells.
Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival.
Gastrointestinal perforation following dabrafenib and trametinib administration in non-small cell lung carcinoma with BRAF V600E mutation: a case report and literature review.
Gefitinib-Resistance Is Related to BIM Expression in Non-Small Cell Lung Cancer Cell Lines.
GINS2 facilitates epithelial-to-mesenchymal transition in non-small-cell lung cancer through modulating PI3K/Akt and MEK/ERK signaling.
HER2 induces cell proliferation and invasion of non-small-cell lung cancer by upregulating COX-2 expression via MEK/ERK signaling pathway.
High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886).
Inhibition of histamine receptor H3 suppresses the growth and metastasis of human non-small cell lung cancer cells via inhibiting PI3K/Akt/mTOR and MEK/ERK signaling pathways and blocking EMT.
Inhibition of Mitogen-Activated Protein Kinase Kinase Alone and in Combination with Anaplastic Lymphoma Kinase (ALK) Inhibition Suppresses Tumor Growth in a Mouse Model of ALK-Positive Lung Cancer.
Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Inhibitory effects of scutellarein on proliferation of human lung cancer A549 cells through ERK and NF?B mediated by the EGFR pathway.
Insulin-like growth factor-1 receptor induces immunosuppression in lung cancer by upregulating B7-H4 expression through the MEK/ERK signaling pathway.
Invasion inhibition by a MEK inhibitor correlates with the actin-based cytoskeleton in lung cancer A549 cells.
KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach.
lncRNA SLC16A1-AS1 as a novel prognostic biomarker in non-small cell lung cancer.
Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer.
Loss of MKK3 and MK2 Copy Numbers in Non-Small Cell Lung Cancer.
MicroRNA-186 suppresses cell proliferation and metastasis through targeting MAP3K2 in non-small cell lung cancer.
MIG-7 and phosphorylated prohibitin coordinately regulate lung cancer invasion/metastasis.
miR-16 regulates proliferation and invasion of lung cancer cells via the ERK/MAPK signaling pathway by targeted inhibition of MAPK kinase 1 (MEK1).
MiR-199a-5p suppresses non-small cell lung cancer via targeting MAP3K11.
Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E (CENP-E) inhibition.
Mitogen-activated protein kinase kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway.
Mutation analysis of the coding sequences of MEK-1 and MEK-2 genes in human lung cancer cell lines.
Neuroendocrine differentiation contributes to radioresistance development and metastatic potential increase in non-small cell lung cancer.
Oestrogen receptor ?5 and epidermal growth factor receptor synergistically promote lung cancer progression.
PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.
Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report.
Population Pharmacokinetic and Exposure-Response Analysis of Selumetinib and Its N-desmethyl Metabolite in Patients With Non-Small Cell Lung Cancer.
RANKL increases migration of human lung cancer cells through intercellular adhesion molecule-1 up-regulation.
Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E-mutated lung adenocarcinoma.
Salidroside represses proliferation, migration and invasion of human lung cancer cells through AKT and MEK/ERK signal pathway.
Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway.
STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway.
The Akt/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy.
The antitumor effect of hinesol, extract from Atractylodes lancea (Thunb.) DC. by proliferation, inhibition, and apoptosis induction via MEK/ERK and NF-?B pathway in non-small cell lung cancer cell lines A549 and NCI-H1299.
Transcriptional Activation of Gstp1 by MEK/ERK Signaling Confers Chemo-Resistance to Cisplatin in Lung Cancer Stem Cells.
Lupus Erythematosus, Systemic
Mesenchymal Stem Cells Activate the MEK/ERK Signaling Pathway and Enhance DNA Methylation via DNMT1 in PBMC from Systemic Lupus Erythematosus.
Lymphatic Metastasis
Aberrant DNA Methylation in Keratoacanthoma.
Comprehensive Analysis of 5-Methylcytosine Profiles of Messenger RNA in Human High-Grade Serous Ovarian Cancer by MeRIP Sequencing.
Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma.
Lymphoma
B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma.
c-Jun NH2-terminal kinase activation leads to a FADD-dependent but Fas ligand-independent cell death in Jurkat T cells.
Cell surface epidermal growth factor receptors increase Src and c-Cbl activity and receptor ubiquitylation.
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Downregulation of CKS1B restrains the proliferation, migration, invasion and angiogenesis of retinoblastoma cells through the MEK/ERK signaling pathway.
EGF Mediates Survival of Rat Cochlear Sensory Cells via an NF-kappaB Dependent Mechanism In Vitro.
Genetic alterations in lung adenocarcinoma with a micropapillary component.
Histiocytic neoplasms in the era of personalized genomic medicine.
IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes.
Inhibition of Mitogen-Activated Protein Kinase Kinase Alone and in Combination with Anaplastic Lymphoma Kinase (ALK) Inhibition Suppresses Tumor Growth in a Mouse Model of ALK-Positive Lung Cancer.
The MAPK/ERK and PI3K pathways additively coordinate the transcription of recombination-activating genes in B lineage cells.
Lymphoma, B-Cell
A Sterol from Soft Coral Induces Apoptosis and Autophagy in MCF-7 Breast Cancer Cells.
Cardiac uses of phosphodiesterase-5 inhibitors.
Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Dietary vitamin C deficiency depresses the growth, head kidney and spleen immunity and structural integrity by regulating NF-?B, TOR, Nrf2, apoptosis and MLCK signaling in young grass carp (Ctenopharyngodon idella).
EGF Mediates Survival of Rat Cochlear Sensory Cells via an NF-kappaB Dependent Mechanism In Vitro.
Isobavachalcone inhibits the proliferation and invasion of tongue squamous cell carcinoma cells.
miR-30d inhibits cell biological progression of Ewing's sarcoma by suppressing the MEK/ERK and PI3K/Akt pathways
Mitogen-activated protein kinases mediate the production of B-cell lymphoma 2 protein by Mycobacterium tuberculosis in monocytes.
Novel Insights of Lymphomagenesis of Helicobacter pylori-Dependent Gastric Mucosa-Associated Lymphoid Tissue Lymphoma.
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Rutin attenuates isoflurane-induced neuroapoptosis via modulating JNK and p38 MAPK pathways in the hippocampi of neonatal rats.
The MAPK/ERK and PI3K pathways additively coordinate the transcription of recombination-activating genes in B lineage cells.
The MEK/ERK pathway acts upstream of NF kappa B1 (p50) homodimer activity and Bcl-2 expression in a murine B-cell lymphoma cell line. MEK inhibition restores radiation-induced apoptosis.
Lymphoma, Large-Cell, Anaplastic
B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma.
Medulloblastoma
Medulloblastoma sensitivity to 17-allylamino-17-demethoxygeldanamycin requires MEK/ERKM.
The micro-RNA 199b-5p regulatory circuit involves Hes1, CD15, and epigenetic modifications in medulloblastoma.
Melanoma
17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
A mitogen-activated protein kinase kinase inhibitor induced compound skin toxicity with oedema in metastatic malignant melanoma.
A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species.
A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma.
Adipocytes contribute to resistance of human melanoma cells to chemotherapy and targeted therapy.
Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy.
Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase.
Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.
ARMS depletion facilitates UV irradiation induced apoptotic cell death in melanoma.
Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted Therapies.
Baicalein restrains proliferation, migration, and invasion of human malignant melanoma cells by down-regulating colon cancer associated transcript-1.
Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.
BRAFV600E Negatively Regulates the AKT Pathway in Melanoma Cell Lines.
CCN2 expression and localization in melanoma cells.
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma.
Dabrafenib in the treatment of advanced melanoma.
Deltex-3-like (DTX3L) stimulates metastasis of melanoma through FAK/PI3K/AKT but not MEK/ERK pathway.
Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation.
Direct targeting of MEK1/2 and RSK2 by silybin induces cell cycle arrest and inhibits melanoma cell growth.
Discovery of Selective Small Molecule Degraders of BRAF-V600E.
DPS-2: A Novel Dual MEK/ERK and PI3K/AKT Pathway Inhibitor with Powerful Ex Vivo and In Vivo Anticancer Properties.
Efficient Suppression of NRAS-Driven Melanoma by Co-inhibition of ERK1/2 and ERK5 MAPK Pathways.
EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma.
ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC).
Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors.
Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers.
Glycoprotein nonmetastatic melanoma protein B extracellular fragment shows neuroprotective effects and activates the PI3K/Akt and MEK/ERK pathways via the Na(+)/K(+)-ATPase.
Harnessing autophagy to overcome mitogen-activated protein kinase kinase inhibitor-induced resistance in metastatic melanoma.
Identification of direct transcriptional targets of BRAF/MEK signalling in melanoma.
Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma.
Inhibition of constitutively activated nuclear factor-kappaB radiosensitizes human melanoma cells.
Inhibition of endoplasmic reticulum stress-induced apoptosis of melanoma cells by the ARC protein.
Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis.
Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model.
Keratoacanthoma, palmoplantar keratoderma developing in an advanced melanoma patient treated with vemurafenib regressed by blockade of mitogen-activated protein kinase kinase signaling.
Lack of BRAF mutations in uveal melanoma.
Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications.
Lymph node metastases of melanoma: challenges for BRAF mutation detection.
Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling.
Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma.
Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review.
Melanoma in congenital melanocytic naevi.
Melanoma therapy: Check the checkpoints.
MicroSCALE screening reveals genetic modifiers of therapeutic response in melanoma.
MKK6 increases the melanocyte dendricity through the regulation of Rho family GTPases.
Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-RafV600E melanoma cells.
Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway.
Neoadjuvant therapy for locally advanced melanoma: new strategies with targeted therapies.
New therapeutic agents in uveal melanoma.
NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma.
Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells.
Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib.
Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series.
Olig2 regulates p53-mediated apoptosis, migration and invasion of melanoma cells.
Oncogenic Activation of MEK/ERK Primes Melanoma Cells for Adaptation to Endoplasmic Reticulum Stress.
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.
Opposite long-term regulation of c-Myc and p27Kip1 through overactivation of Raf-1 and the MEK/ERK module in proliferating human choroidal melanoma cells.
Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling.
p38 MAP kinase is necessary for melanoma-mediated regulation of VE-cadherin disassembly.
P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.
Pharmacogenomics of metabotropic glutamate receptor subtype 1 and in vivo malignant melanoma formation.
Pimasertib-associated ophthalmological adverse events.
Platelet-derived growth factor-receptor alpha strongly inhibits melanoma growth in vitro and in vivo.
POU4F1 promotes the resistance of melanoma to BRAF inhibitors through MEK/ERK pathway activation and MITF up-regulation.
Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma.
Ras mediates the cAMP-dependent activation of extracellular signal-regulated kinases (ERKs) in melanocytes.
Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma.
Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors.
Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma.
Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.
Resveratrol inhibits proliferation, promotes differentiation and melanogenesis in HT-144 melanoma cells through inhibition of MEK/ERK kinase pathway.
Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.
Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.
Serum 5-S-cysteinyl-dopa levels as a predictive marker for the efficacy of nivolumab in advanced malignant melanoma.
Signaling networks in cutaneous melanoma metastasis identified by complementary DNA microarrays.
Specific amino acid deficiency alters the expression of genes in human melanoma and other tumor cell lines.
Sustained IRE1 and ATF6 signaling is important for survival of melanoma cells undergoing ER stress.
Targeted Therapy in Melanoma and Mechanisms of Resistance.
Targeted-gene silencing of BRAF to interrupt BRAF/MEK/ERK pathway synergized photothermal therapeutics for melanoma using a novel FA-GNR-siBRAF nanosystem.
Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.
Targeting NRAS in melanoma.
The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.
Treatment of Advanced Melanoma: Past, Present and Future.
Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade.
Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?
U0126, a mitogen-activated protein kinase kinase inhibitor, inhibits the invasion of human A375 melanoma cells.
Usefulness of serum 5-S-cysteinyl-dopa as a biomarker for predicting prognosis and detecting relapse in patients with advanced stage malignant melanoma.
WNT1-inducible signaling pathway protein 1 (WISP1/CCN4) stimulates melanoma invasion and metastasis by promoting the epithelial - mesenchymal transition.
Melanoma, Experimental
Mechanism of pigmentation by minocycline in murine B16 melanoma cells.
Memory Disorders
Activation of Glycogen Synthase Kinase-3 Mediates the Olfactory Deficit-Induced Hippocampal Impairments.
Extracellular signal-regulated kinase activity in the entorhinal cortex is necessary for long-term spatial memory.
Meningioma
CXCR4 and SDF1 expression in human meningiomas: a proliferative role in tumoral meningothelial cells in vitro.
mitogen-activated protein kinase kinase deficiency
Mitogen-activated protein kinase kinase 4 deficiency in cardiomyocytes causes connexin 43 reduction and couples hypertrophic signals to ventricular arrhythmogenesis.
Mouth Neoplasms
Areca nut components stimulate ADAM17, IL-1?, PGE2 and 8-isoprostane production in oral keratinocyte: role of reactive oxygen species, EGF and JAK signaling.
Benzo (a) pyrene induced tumorigenesity of human immortalized oral epithelial cells: transcription profiling.
Duchesnea indica extract attenuates oral cancer cells metastatic potential through the inhibition of the matrix metalloproteinase-2 activity by down-regulating the MEK/ERK pathway.
MicroRNA-1179 suppresses the proliferation and enhances vincristine sensitivity of oral cancer cells via induction of apoptosis and modulation of MEK/ERK and PI3K/AKT signalling pathways.
Xanthoxyletin Inhibits Proliferation of Human Oral Squamous Carcinoma Cells and Induces Apoptosis, Autophagy, and Cell Cycle Arrest by Modulation of the MEK/ERK Signaling Pathway.
Mucositis
Efficacy of Azatyrosine-Phenylbutyric Hydroxamides, a Histone Deacetylase Inhibitor, on Chemotherapy-Induced Gastrointestinal Mucositis.
Multiple Myeloma
Circular RNA Protein Tyrosine Kinase 2 Promotes Cell Proliferation, Migration and Suppresses Apoptosis via Activating MicroRNA-638 Mediated MEK/ERK, WNT/?-Catenin Signaling Pathways in Multiple Myeloma.
Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells.
Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.
Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells.
Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines.
Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation.
Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells.
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.
The increased expression of receptor activator of nuclear-kappaB ligand (RANKL) of multiple myeloma bone marrow stromal cells is inhibited by the bisphosphonate ibandronate.
Muscular Dystrophies
P38? MAPK underlies muscular dystrophy and myofiber death through a Bax-dependent mechanism.
Myocardial Infarction
Overexpression of mitogen-activated protein kinase kinase 6 in the heart improves functional recovery from ischemia in vitro and protects against myocardial infarction in vivo.
Post-infarction remodeling is independent of mitogen-activated protein kinase kinase 3 (MKK3).
Qishen capsule safely boosts cardiac function and angiogenesis via the MEK/ERK pathway in a rat myocardial infarction model.
Rosuvastatin enhances the therapeutic efficacy of adipose-derived mesenchymal stem cells for myocardial infarction via PI3K/Akt and MEK/ERK pathways.
Myocarditis
CVB3 Nonstructural 2A Protein Modulates SREBP1a Signaling via the MEK/ERK Pathway.
Nasopharyngeal Carcinoma
MiR-101 promotes nasopharyngeal carcinoma cell apoptosis through inhibiting Ras/Raf/MEK/ERK signaling pathway.
Overexpression of BPIFB1 promotes apoptosis and inhibits proliferation via the MEK/ERK signal pathway in nasopharyngeal carcinoma.
Tetrandrine sensitizes nasopharyngeal carcinoma cells to irradiation by inducing autophagy and inhibiting MEK/ERK pathway.
Nasopharyngeal Neoplasms
Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines.
Eriodictyol inhibits the growth of CNE1 human nasopharyngeal cancer growth by targeting MEK/ERK signalling pathway, inducing cellular autophagy and inhibition of cell migration and invasion.
Neoplasm Metastasis
"MKK4 suppresses metastatic colonization by multiple highly metastatic prostate cancer cell lines through a transient impairment in cell cycle progression"
(-)-Epigallocatechin-3-gallate inhibits osteosarcoma cell invasiveness by inhibiting the MEK/ERK signaling pathway in human osteosarcoma cells.
3-Hydroxyflavone inhibits human osteosarcoma U2OS and 143B cells metastasis by affecting EMT and repressing u-PA/MMP-2 via FAK-Src to MEK/ERK and RhoA/MLC2 pathways and reduces 143B tumor growth inĀ vivo.
A Ferulic Acid Derivative FXS-3 Inhibits Proliferation and Metastasis of Human Lung Cancer A549 Cells via Positive JNK Signaling Pathway and Negative ERK/p38, AKT/mTOR and MEK/ERK Signaling Pathways.
Aberrant DNA Methylation in Keratoacanthoma.
Alpha-Mangostin Suppresses the Metastasis of Human Renal Carcinoma Cells by Targeting MEK/ERK Expression and MMP-9 Transcription Activity.
Analysis of the mitogen-activated protein kinase kinase 4 (MAP2K4) tumor suppressor gene in ovarian cancer.
Annexin A3 Knockdown Suppresses Lung Adenocarcinoma.
Bone morphogenetic protein 2 mediates epithelial-mesenchymal transition via AKT and ERK signaling pathways in gastric cancer.
Building on the foundation of daring hypotheses: using the MKK4 metastasis suppressor to develop models of dormancy and metastatic colonization.
Cellular mechanisms of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MAPK signaling in hepatocellular carcinoma.
CircRNA CDR1as/miR-1287/Raf1 Axis Modulates Hepatocellular Carcinoma Progression Through MEK/ERK Pathway.
Comprehensive Analysis of 5-Methylcytosine Profiles of Messenger RNA in Human High-Grade Serous Ovarian Cancer by MeRIP Sequencing.
CSE1L silence inhibits the growth and metastasis in gastric cancer by repressing GPNMB via positively regulating transcription factor MITF.
Deltex-3-like (DTX3L) stimulates metastasis of melanoma through FAK/PI3K/AKT but not MEK/ERK pathway.
Downregulation of phosphorylated MKK4 is associated with a poor prognosis in colorectal cancer patients.
EntelonĀ® (Vitis vinifera Seed Extract) Prevents Cancer Metastasis via the Downregulation of Interleukin-1 Alpha in Triple-Negative Breast Cancer Cells.
Epiregulin as a therapeutic target in non-small-cell lung cancer.
Fisetin Suppresses the Proliferation and Metastasis of Renal Cell Carcinoma through Upregulation of MEK/ERK-Targeting CTSS and ADAM9.
Friedelin inhibits the growth and metastasis of human leukemia cells via modulation of MEK/ERK and PI3K/AKT signalling pathways.
Hematopoietic cell kinase enhances osteosarcoma development via the MEK/ERK pathway.
Hypoxic tumor-derived exosomal miR-31-5p promotes lung adenocarcinoma metastasis by negatively regulating SATB2-reversed EMT and activating MEK/ERK signaling.
Impact of IFNalpha2b upon pSTAT3 and the MEK/ERK MAPK pathway in melanoma.
Inhibition of histamine receptor H3 suppresses the growth and metastasis of human non-small cell lung cancer cells via inhibiting PI3K/Akt/mTOR and MEK/ERK signaling pathways and blocking EMT.
Insulin promotes proliferation, survival, and invasion in endometrial carcinoma by activating the MEK/ERK pathway.
Invasion inhibition by a MEK inhibitor correlates with the actin-based cytoskeleton in lung cancer A549 cells.
Kinesin family member 2C promotes hepatocellular carcinoma growth and metastasis via activating MEK/ERK pathway.
Lack of BRAF mutations in uveal melanoma.
LDLR inhibition promotes hepatocellular carcinoma proliferation and metastasis by elevating intracellular cholesterol synthesis through the MEK/ERK signaling pathway.
LncRNA HOXA-AS3 Sponges miR-29c to Facilitate Cell Proliferation, Metastasis, and EMT Process and Activate the MEK/ERK Signaling Pathway in Hepatocellular Carcinoma.
Long non-coding RNA AL139002.1 promotes gastric cancer development by sponging microRNA-490-3p to regulate Hepatitis A Virus Cellular Receptor 1 expression.
MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.
Metastasis suppressor genes: basic biology and potential clinical use.
Methylation-dependent MCM6 repression induced by LINC00472 inhibits triple-negative breast cancer metastasis by disturbing the MEK/ERK signaling pathway.
MicroRNA-335 targets the MEK/ERK pathway to regulate the proliferation and metastasis of colon cancer.
MicroRNA-338-3p suppresses ovarian cancer cells growth and metastasis: implication of Wnt/catenin beta and MEK/ERK signaling pathways.
miR-665 expression predicts poor survival and promotes tumor metastasis by targeting NR4A3 in breast cancer.
Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis.
Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma.
Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers.
Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17.
Modeling MEK4 Kinase Inhibitors through Perturbed Electrostatic Potential Charges.
Neferine inhibits MDA-MB-231?cells growth and metastasis by regulating miR-374a/FGFR-2.
Nitric Oxide (NO) and NO Synthases (NOS)-Based Targeted Therapy for Colon Cancer.
Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers.
Puerarin inhibits M2 polarization and metastasis of tumor-associated macrophages from NSCLC xenograft model via inactivating MEK/ERK 1/2 pathway.
Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway.
Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway.
SERPINA11 Inhibits Metastasis in Hepatocellular Carcinoma by Suppressing MEK/ERK Signaling Pathway.
Serum Proteomic Signatures of Male Breast Cancer.
Signaling networks in cutaneous melanoma metastasis identified by complementary DNA microarrays.
Specific amino acid deficiency alters the expression of genes in human melanoma and other tumor cell lines.
STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
Targeting Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase in the Mutant (V600E) B-Raf Signaling Cascade Effectively Inhibits Melanoma Lung Metastases.
The novel long noncoding RNA AU021063, induced by IL-6/Arid5a signaling, exacerbates breast cancer invasion and metastasis by stabilizing Trib3 and activating the Mek/Erk pathway.
Time-dependent transcriptional profiling links gene expression to mitogen-activated protein kinase kinase 4 (MKK4)-mediated suppression of omental metastatic colonization.
Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade.
Upregulation of lncRNA ADAMTS9-AS2 Promotes Salivary Adenoid Cystic Carcinoma Metastasis via PI3K/Akt and MEK/Erk Signaling.
[Expression of MEK/ERK signal pathways in renal cell carcinoma with bone metastasis].
[Progress of anti-tumor study based on BRAF].
[The relationship between expression of mitogen-activated protein kinase kinase 4 and metastasis in oral squamous cell carcinoma].
Neoplasms
(18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors.
3-Hydroxyflavone inhibits human osteosarcoma U2OS and 143B cells metastasis by affecting EMT and repressing u-PA/MMP-2 via FAK-Src to MEK/ERK and RhoA/MLC2 pathways and reduces 143B tumor growth inĀ vivo.
3D-QSAR and molecular docking studies on substituted isothiazole analogs as inhibitors against MEK-1 kinase.
?-Chaconine isolated from a Solanum tuberosum L. cv Jayoung suppresses lipopolysaccharide-induced pro-inflammatory mediators via AP-1 inactivation in RAW 264.7 macrophages and protects mice from endotoxin shock.
A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway.
A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib.
A Mortalin/HSPA9-Mediated Switch in Tumor-Suppressive Signaling of Raf/MEK/Extracellular Signal-Regulated Kinase.
A new prognosis prediction model combining TNM stage with MAP2K4 and JNK in postoperative pancreatic cancer patients.
A Novel Ribonuclease from Rana Chensinensis and Its Potential for the Treatment of Human Breast Cancer.
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
A plate-based assay to measure cellular ERK substrate phosphorylation: utility for drug discovery of the MAPK-signaling cascade.
A precisely regulated gene expression cassette potently modulates metastasis and survival in multiple solid cancers.
A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker.
A tumor-associated splice-isoform of MAP2K7 drives dedifferentiation in MBNL1-low cancers via JNK activation.
Activated MEK/ERK Pathway Drives Widespread and Coordinated Overexpression of UHRF1 and DNMT1 in Cancer cells.
Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ.
Activation of integrin alpha(V)beta(3) regulates cell adhesion and migration to bone sialoprotein.
Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell-conditioned medium.
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
ADP-ribosylation factor 6 regulates tumor cell invasion through the activation of the MEK/ERK signaling pathway.
AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer.
Analysis of invasion-metastasis mechanism in pancreatic cancer: involvement of tight junction transmembrane protein occludin and MEK/ERK signal transduction pathway in cancer cell dissociation.
Analysis of the mitogen-activated protein kinase kinase 4 (MAP2K4) tumor suppressor gene in ovarian cancer.
Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model.
Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression.
Anethole blocks both early and late cellular responses transduced by tumor necrosis factor: effect on NF-kappaB, AP-1, JNK, MAPKK and apoptosis.
Anthrax lethal factor causes proteolytic inactivation of mitogen-activated protein kinase kinase.
Anti-inflammatory action of herbal medicine comprised of Scutellaria baicalensis and Chrysanthemum morifolium.
Anti-inflammatory Effects of Oxymatrine Through Inhibition of Nuclear Factor-kappa B and Mitogen-activated Protein Kinase Activation in Lipopolysaccharide-induced BV2 Microglia Cells.
Antitumor activity of the MEK inhibitor trametinib on intestinal polyp formation in Apc(?716) mice involves stromal COX-2.
Arrangement of expression and distribution of tight junction protein claudin-1 in cell dissociation of pancreatic cancer cells.
Artesunate induces apoptosis and inhibits the proliferation, stemness, and tumorigenesis of leukemia.
Atypical protein kinase C iota expression and aurothiomalate sensitivity in human lung cancer cells.
Baicalin Suppresses Bilirubin-Induced Apoptosis and Inflammation by Regulating p38 Mitogen-Activated Protein Kinases (MAPK) Signaling in Neonatal Neurons.
Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer.
Bcl-2-mediated cell survival promotes metastasis of EpH4 betaMEKDD mammary epithelial cells.
Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells.
Bioactive compounds in plant materials for the prevention of diabetesand obesity.
Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation.
Blockade of ?7 nicotinic acetylcholine receptors inhibit nicotine-induced tumor growth and vimentin expression in non-small cell lung cancer through MEK/ERK signaling way.
Blockage of progesterone receptor effectively protects pancreatic islet beta cell viability.
Bone morphogenetic protein 2 mediates epithelial-mesenchymal transition via AKT and ERK signaling pathways in gastric cancer.
Bovine lactoferrin protects RSC96 Schwann cells from tumor necrosis factor-alpha-induced growth arrest via extracellular-signal-regulated kinase 1/2.
BRAF inhibitor therapy in HCL.
BRAF mutation predicts sensitivity to MEK inhibition.
BRAF mutation testing in clinical practice.
Building on the foundation of daring hypotheses: using the MKK4 metastasis suppressor to develop models of dormancy and metastatic colonization.
C6orf106 accelerates pancreatic cancer cell invasion and proliferation via activating ERK signaling pathway.
Ca(2+)/calmodulin-dependent protein kinase II promotes cell cycle progression by directly activating MEK1 and subsequently modulating p27 phosphorylation.
Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms.
Cancer stem cell generation by silenced MAPK enhancing PI3K/AKT signaling.
CD40 signaling of monocyte inflammatory cytokine synthesis through an ERK1/2-dependent pathway. A target of interleukin (il)-4 and il-10 anti-inflammatory action.
Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.
Characterization of Activating Mutations of the MEK1 Gene in Papillary Thyroid Carcinomas.
Cinobufotalin powerfully reversed EBV-miR-BART22-induced cisplatin resistance via stimulating MAP2K4 to antagonize non-muscle myosin heavy chain IIA/glycogen synthase 3?/?-catenin signaling pathway.
CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo.
Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions.
Clinical implications of the Hippo-YAP pathway in multiple cancer contexts.
Clinicopathologic and prognostic significance of MKK4 and MKK7 in resectable pancreatic ductal adenocarcinoma.
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines.
Combination of SB431542, CHIR99021 and PD0325901 has a synergic effect on abrogating valproic acid?induced epithelial?mesenchymal transition and stemness in HeLa, 5637 and SCC?15 cells.
Combined MEK and PI3K/p110? Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.
Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.
Commentary on Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C, Department of Urology, Columbia University College of Physicians and Surgeons, New York, NY.
Comparative proteomics of human embryonic stem cells and embryonal carcinoma cells.
Comprehensive Analysis of 5-Methylcytosine Profiles of Messenger RNA in Human High-Grade Serous Ovarian Cancer by MeRIP Sequencing.
Concomitant activation of MEK-1 and Rac-1 increases the proliferative potential of thyroid epithelial cells, without affecting their differentiation.
Concurrent inhibition of ErbB family and MEK/ERK kinases to suppress non-small cell lung cancer proliferation.
Constitutive Activation of Mitogen-activated Protein Kinase Kinase (MEK1) in Ileal Enterocytes Leads to Dysplasia and a Predisposition to Cancer.
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation.
Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.
Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling.
Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia.
Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions.
CSE1L silence inhibits the growth and metastasis in gastric cancer by repressing GPNMB via positively regulating transcription factor MITF.
Cytokine-activated p42/p44 MAP kinase is involved in inducible nitric oxide synthase gene expression independent from NF-kappaB activation in vascular smooth muscle cells.
Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth.
Deciphering signaling pathways in vivo: the Ras/Raf/MEK/ERK cascade.
Decrease in K-ras p21 and increase in Raf1 and activated Erk 1 and 2 in murine lung tumors initiated by N-nitrosodimethylamine and promoted by 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Delphinidin attenuates neoplastic transformation in JB6 Cl41 mouse epidermal cells by blocking Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling.
Dermokine-? impairs ERK signaling through direct binding to GRP78.
Desacetyluvaricin induces S phase arrest in SW480 colorectal cancer cells through superoxide overproduction.
Differential Activation of ERK Signaling in HPV-Related Oropharyngeal Squamous Cell Carcinoma.
Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.
Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening.
Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.
DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.
Down-regulation of Aquaporin-1 mediates a microglial phenotype switch affecting glioma growth.
Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers.
Dual Activity of Ginsenoside Rb1 in Hypertrophic Cardiomyocytes and Activated Macrophages: Implications for the Therapeutic Intervention of Cardiac Hypertrophy.
Editorial comment on: Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: Dose dependency and modulation of biomarkers.
Efficient Suppression of NRAS-Driven Melanoma by Co-inhibition of ERK1/2 and ERK5 MAPK Pathways.
Eicosapentaenoic acid and docosahexaenoic acid inhibit macrophage-induced gastric cancer cell migration by attenuating the expression of matrix metalloproteinase 10.
Elevated expression of ERK 2 in human tumor cells chronically treated with PD98059.
Elevated hydrostatic pressure enhances the motility and enlarges the size of the lung cancer cells through aquaporin upregulation mediated by caveolin-1 and ERK1/2 signaling.
Eliminating animal facility light-at-night contamination and its effect on circadian regulation of rodent physiology, tumor growth, and metabolism: a challenge in the relocation of a cancer research laboratory.
Enhancement of the antitumor effect of HER2-directed CAR-T cells through blocking epithelial-mesenchymal transition in tumor cells.
Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants.
Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways.
Epiregulin as a therapeutic target in non-small-cell lung cancer.
ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.
Erythropoietin inhibits gluconeogenesis and inflammation in the liver and improves glucose intolerance in high-fat diet-fed mice.
Essential genes shape cancer genomes through linear limitation of homozygous deletions.
Essential, non-redundant roles of B-Raf and Raf-1 in Ras-driven skin tumorigenesis.
Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.
Evaluation of kinase inhibitors as potential therapeutics for flavivirus infections.
Exosomes Released by Gastric Cancer Cells Induce Transition of Pericytes Into Cancer-Associated Fibroblasts.
Expression and mutation analyses of MKK4, a candidate tumour suppressor gene encoded by chromosome 17p, in human gastric adenocarcinoma.
Expression and prognostic role of MEKK3 and pERK in patients with renal clear cell carcinoma.
Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors.
Favourable prognosis in medulloblastoma with extensive nodularity is associated with mitogen-activated protein kinase upregulation.
Fc gamma R-dependent mitogen-activated protein kinase activation in leukocytes: a common signal transduction event necessary for expression of TNF-alpha and early activation genes.
FGF-1/-3/FGFR4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and MMP-7.
FGFR3 Deficiency Causes Multiple Chondroma-like Lesions by Upregulating Hedgehog Signaling.
Fluorinated thiazolidinol drives autophagic cell death in pancreatic cancer cells via AMPK activation and perturbation of critical sentinels of oncogenic signaling.
FOXO3a from the Nucleus to the Mitochondria: A Round Trip in Cellular Stress Response.
Future Aspects for Cannabinoids in Breast Cancer Therapy.
Gatekeeper mutations mediate resistance to BRAF-targeted therapies.
Geldanamycin and its anti-cancer activities.
Gene expression profiles in liver of mouse after chronic exposure to drinking water.
Genetic and molecular alterations in rhabdomyosarcoma: mRNA overexpression of MCL1 and MAP2K4 genes.
Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases.
Genistein-induced differentiation of breast cancer stem/progenitor cells through a paracrine mechanism.
Globularifolin exerts anticancer effects on glioma U87Ā cells through inhibition of Akt/mTOR and MEK/ERK signaling pathways in vitro and inhibits tumor growth in vivo.
Glucocorticoids Suppress Selected Components of the Senescence-Associated Secretory Phenotype.
Glycyrrhizic Acid Modulates Apoptosis through Extrinsic/Intrinsic Pathways and Inhibits Protein Kinase B- and Extracellular Signal-Regulated Kinase-Mediated Metastatic Potential in Hepatocellular Carcinoma In Vitro and In Vivo.
GPR30-mediated HMGB1 upregulation in CAFs induces autophagy and tamoxifen resistance in ER?-positive breast cancer cells.
HAVCR1 Affects the MEK/ERK Pathway in Gastric Adenocarcinomas and Influences Tumor Progression and Patient Outcome.
Hepatitis B virus core protein sensitizes hepatocytes to tumor necrosis factor-induced apoptosis by suppression of the phosphorylation of mitogen-activated protein kinase kinase 7.
Histiocytic neoplasms in the era of personalized genomic medicine.
Hit identification of SMYD3 enzyme inhibitors using structure-based pharmacophore modeling.
Homozygous Deletion of MKK4 in Ovarian Serous Carcinoma.
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
HSP70 inhibitor VER155008 suppresses pheochromocytoma cell and xenograft growth by inhibition of PI3K/AKT/mTOR and MEK/ERK pathways.
Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor.
Hypoxia-induced acetylation of PAK1 enhances autophagy and promotes brain tumorigenesis via phosphorylating ATG5.
Hypoxia-Induced S100A8 Expression Activates Microglial Inflammation and Promotes Neuronal Apoptosis.
Hypoxic tumor-derived exosomal miR-31-5p promotes lung adenocarcinoma metastasis by negatively regulating SATB2-reversed EMT and activating MEK/ERK signaling.
IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment.
Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death.
In silico investigation of new binding pocket for mitogen activated kinase kinase (MEK): Development of new promising inhibitors.
In vivo effect of alpha-bisabolol, a nontoxic sesquiterpene alcohol, on the induction of spontaneous mammary tumors in HER-2/neu transgenic mice.
Increased Adipose Tissue Expression of Proinflammatory CD40, MKK4 and JNK in Patients with Very Severe Chronic Obstructive Pulmonary Disease.
Increased MAPK expression and activity in primary human hepatocellular carcinoma.
Increased STAT-3 and synchronous activation of Raf-1-MEK-1-MAPK, and phosphatidylinositol 3-Kinase-Akt-mTOR pathways in atypical and anaplastic meningiomas.
Induction of integrin ?3 by sustained ERK activity promotes the invasiveness of TGF?-induced mesenchymal tumor cells.
Infrequent but high-level amplification of 17p11.2 approximately p12 in human glioma.
Inhibiting CCN1 blocks AML cell growth by disrupting the MEK/ERK pathway.
Inhibition of Apolipoprotein AI Gene Expression by Tumor Necrosis Factor alpha: Roles for MEK/ERK and JNK Signaling.
Inhibition of c-Myc down-regulation by sustained extracellular signal-regulated kinase activation prevents the antimetabolite methotrexate- and gemcitabine-induced differentiation in non-small-cell lung cancer cells.
Inhibition of conjugated linoleic acid on mouse forestomach neoplasia induced by benzo (a) pyrene and chemopreventive mechanisms.
Inhibition of Doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by Sorafenib: the role of extracellular signal-regulated kinase counteraction.
Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
Inhibition of fatty acid transport and proliferative activity in tissue-isolated human squamous cell cancer xenografts perfused in situ with melatonin or eicosapentaenoic or conjugated linoleic acids.
Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells.
Inhibition of Mitogen-Activated Protein Kinase Kinase Alone and in Combination with Anaplastic Lymphoma Kinase (ALK) Inhibition Suppresses Tumor Growth in a Mouse Model of ALK-Positive Lung Cancer.
Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.
Insulin receptor, insulin receptor substrate-1, Raf-1, and Mek-1 during hormonal hepatocarcinogenesis by intrahepatic pancreatic islet transplantation in diabetic rats.
Integrative pan-cancer analysis of MEK1 aberrations and the potential clinical implications.
Interplay of T-cell receptor and interleukin-2 signalling in Vgamma2Vdelta2 T-cell cytotoxicity.
Intestinal epithelial cancer cell anoikis resistance: EGFR-mediated sustained activation of Src overrides Fak-dependent signaling to MEK/Erk and/or PI3-K/Akt-1.
Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors.
Investigation of the Mek-MAP kinase-Rsk pathway in human breast cancer.
JNKK1 organizes a MAP kinase module through specific and sequential interactions with upstream and downstream components mediated by its amino-terminal extension.
Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population.
KrasG12D mutation contributes to regulatory T cell conversion through activation of the MEK/ERK pathway in pancreatic cancer.
KRASG12D- and BRAFV600E-Induced Transformation of Murine Pancreatic Epithelial Cells Requires MEK/ERK-Stimulated IGF1R Signaling.
KrĆ¼ppel-like factor 5 promotes apoptosis triggered by tumor necrosis factor ? in LNCaP prostate cancer cells via up-regulation of mitogen-activated protein kinase kinase 7.
Lack of BRAF mutations in uveal melanoma.
Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy.
LIM and SH3 protein 1 knockdown suppresses proliferation and metastasis of colorectal carcinoma cells via inhibition of the mitogen-activated protein kinase signaling pathway.
Loss of MKK3 and MK2 Copy Numbers in Non-Small Cell Lung Cancer.
Mammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes.
Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor ?2 expression.
Map2k4? - Identification and functional characterization of a novel Map2k4 splice variant.
MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models.
MAP3K11 is a tumor suppressor targeted by the oncomiR miR-125b in early B cells.
MAPK kinase 3 is a tumor suppressor with reduced copy number in breast cancer.
MAPK pathway alterations correlate with poor survival and drive resistance to therapy in patients with lung cancers driven by ROS1 fusions.
MAPK7 and MAP2K4 as prognostic markers in osteosarcoma.
Mass spectrometry-based proteomics reveals potential roles of NEK9 and MAP2K4 in resistance to PI3K inhibitors in triple negative breast cancers.
Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK.
MED12 controls the response to multiple cancer drugs through regulation of TGF-? receptor signaling.
Medulloblastoma sensitivity to 17-allylamino-17-demethoxygeldanamycin requires MEK/ERKM.
MEK inhibition increases lapatinib sensitivity via modulation of FOXM1.
MEK inhibition induces caspases activation, differentiation blockade and PML/RARalpha degradation in acute promyelocytic leukaemia.
MEK inhibition prevents tumour-shed transforming growth factor-?-induced T-regulatory cell augmentation in tumour milieu.
MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701.
MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumors.
MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma.
MEK/ERK signaling is a critical regulator of high-risk human papillomavirus oncogene expression revealing therapeutic targets for HPV-induced tumors.
MEK/ERK signaling pathway in apoptosis of SW620 cell line and inhibition effect of resveratrol.
MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells.
MEK1 and MEK2 isoforms regulate distinct functions in pancreatic cancer cells.
MEK2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment.
MEKKs, GCKs, MLKs, PAKs, TAKs, and tpls: upstream regulators of the c-Jun amino-terminal kinases?
Melanoma in congenital melanocytic naevi.
Metalloprotease-dependent activation of EGFR modulates CD44(+)/CD24(-) populations in triple negative breast cancer cells through the MEK/ERK pathway.
microRNA-124-3p inhibits tumourigenesis by targeting mitogen-activated protein kinase 4 in papillary thyroid carcinoma.
MicroRNA-216a-3p promotes sorafenib sensitivity in hepatocellular carcinoma by downregulating MAPK14 expression.
microRNA-363 plays a tumor suppressive role in osteosarcoma by directly targeting MAP2K4.
MicroRNA-802 plays a tumour suppressive role in tongue squamous cell carcinoma through directly targeting MAP2K4.
MicroRNA?136 inhibits prostate cancer cell proliferation and invasion by directly targeting mitogen?activated protein kinase kinase 4.
miR-125b inhibited epithelial-mesenchymal transition of triple-negative breast cancer by targeting MAP2K7.
miR-199a Regulates the Tumor Suppressor Mitogen-Activated Protein Kinase Kinase Kinase 11 in Gastric Cancer.
MiR-199a-5p suppresses non-small cell lung cancer via targeting MAP3K11.
MiR-744-5p inducing cell death by directly targeting HNRNPC and NFIX in ovarian cancer cells.
MiR-92b-3p ameliorates inflammation and autophagy by targeting TRAF3 and suppressing MKK3-p38 pathway in caerulein-induced AR42J cells.
Mirk kinase inhibition targets ovarian cancer ascites.
Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E (CENP-E) inhibition.
Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.
Mitogen-activated protein kinase kinase 3 induces cell cycle arrest via p38 activation mediated Bmi-1 downregulation in hepatocellular carcinoma.
Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis.
Mitogen-Activated Protein Kinase Kinase 4 Gene Polymorphism and Cancer Risk.
Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers.
Mitogen-activated protein kinases mediate the production of B-cell lymphoma 2 protein by Mycobacterium tuberculosis in monocytes.
Mixed lineage kinase 3 inhibition induces T cell activation and cytotoxicity.
Mobile element insertions and associated structural variants in longitudinal breast cancer samples.
Modulation of expression of 17-Hydroxylase/17,20 lyase (CYP17) and P450 aromatase (CYP19) by inhibition of MEK1 in a human ovarian granulosa-like tumor cell line.
Molecular Mechanisms and Therapeutic Potential of miR-493 in Cancer.
Molecular mechanisms for the p38-induced cellular senescence in normal human fibroblast.
Molecular Mechanisms of Anticancer Activities of Puerarin.
mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?
Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function.
Mutation analyses of 268 candidate genes in human tumor cell lines.
Mutation rate of MAP2K4/MKK4 in breast carcinoma.
Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
Mycobacterium tuberculosis Lipoprotein and Lipoglycan Binding to Toll-Like Receptor 2 Correlates with Agonist Activity and Functional Outcomes.
Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1.
Nanosized Modification Strategies for Improving the Antitumor Efficacy of MEK Inhibitors.
Network analysis of skin tumor progression identifies a rewired genetic architecture affecting inflammation and tumor susceptibility.
Neuroendocrine differentiation contributes to radioresistance development and metastatic potential increase in non-small cell lung cancer.
NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma.
Nitric Oxide (NO) and NO Synthases (NOS)-Based Targeted Therapy for Colon Cancer.
Non-autonomous regulation of germline stem cell proliferation by somatic MPK-1/MAPK activity in C.Ā elegans.
Notch Pathway Inhibition Using PF-03084014, a ?-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.
Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth.
Nuclear receptor CAR represses TNFalpha-induced cell death by interacting with the anti-apoptotic GADD45B.
O Cdc7 kinase where art thou?
O-GlcNAcylation of MEK2 promotes the proliferation and migration of breast cancer cells.
Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression.
Oncogenic K-Ras Regulates Bioactive Sphingolipids in a Sphingosine Kinase 1-dependent Manner.
Oncogenic NRAS, required for pathogenesis of embryonic rhabdomyosarcoma, relies upon the HMGA2-IGF2BP2 pathway.
Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
Overactivation of Akt Contributes to MEK Inhibitor Primary and Acquired Resistance in Colorectal Cancer Cells.
Overactivation of the MEK/ERK pathway in liver tumor cells confers resistance to TGF-{beta}-induced cell death through impairing up-regulation of the NADPH oxidase NOX4.
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy.
Overexpressed microRNA-136 works as a cancer suppressor in gallbladder cancer through suppression of JNK signaling pathway via inhibition of MAP2K4.
Overexpression of miR-199a-5p decreases esophageal cancer cell proliferation through repression of mitogen-activated protein kinase kinase kinase-11 (MAP3K11).
Oxidative Stress in Malignant Melanoma Enhances Tumor Necrosis Factor-? Secretion of Tumor-Associated Macrophages That Promote Cancer Cell Invasion.
P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.
p38 MAP kinase and MKK-1 co-operate in the generation of GM-CSF from LPS-stimulated human monocytes by an NF-kappa B-independent mechanism.
p38 MAPK signaling in M1 macrophages results in selective elimination of M2 macrophages by MEK inhibition.
PAC exhibits potent anti-colon cancer properties through targeting cyclin D1 and suppressing epithelial-to-mesenchymal transition.
PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via ?-catenin-mediated stemness.
Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2.
Paradoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cells.
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion.
PD98059 triggers G1 arrest and apoptosis in human leukemic U937 cells through downregulation of Akt signal pathway.
Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types.
Peroxisome proliferators activate extracellular signal-regulated kinases in immortalized mouse liver cells.
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
Phospho-ERK levels as predictors for chemotherapy of rectal carcinoma.
Phosphorylation of myofibrillogenesis regulator-1 activates the MAPK signaling pathway and induces proliferation and migration in human breast cancer MCF7 cells.
PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells.
PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma.
Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma.
Pro-Renin Receptor Overexpression Promotes Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Apolipoprotein E-Knockout Mice.
Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E ?-tocotrienol.
Purification and cDNA cloning of SAPKK3, the major activator of RK/p38 in stress- and cytokine-stimulated monocytes and epithelial cells.
Purification and identification of a major activator for p38 from osmotically shocked cells. Activation of mitogen-activated protein kinase kinase 6 by osmotic shock, tumor necrosis factor-alpha, and H2O2.
Racial Disparities in the Molecular Landscape of Cancer.
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Raf kinases in cancer-roles and therapeutic opportunities.
RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors.
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
RAS/MAPK signaling functions in oxidative stress, DNA damage response and cancer progression.
RASSF9 promotes NSCLC cell proliferation by activating the MEK/ERK axis.
Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma.
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis.
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models.
Regulation of type I plasminogen activator inhibitor in human gingival fibroblasts with cyclosporine A.
Relationship between the expression of extracellular signal-regulated kinase 1/2 and the dissociation of pancreatic cancer cells: Involvement of ERK1/2 in the dissociation status of cancer cells.
Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for tumor necrosis factor-induced cytokine expression.
Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras.
REX-1 Represses RASSF1a and Activates the MEK/ERK Pathway to Promote Tumorigenesis in Prostate Cancer.
RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo.
RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.
Role of erbB3 receptors in cancer therapeutic resistance.
Role of MEK partner-1 in cancer stemness through MEK/ERK pathway in cancerous neural stem cells, expressing EGFRviii.
Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells.
Role of mitogen-activated protein kinase kinase 4 in cancer.
Selected polyphenols potentiate the apoptotic efficacy of glycolytic inhibitors in human acute myeloid leukemia cell lines. Regulation by protein kinase activities.
Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines.
Selumetinib attenuate skeletal muscle wasting in murine cachexia model through ERK inhibition and AKT activation.
Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway.
SGK1 inhibits cellular apoptosis and promotes proliferation via the MEK/ERK/p53 pathway in colitis.
Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes.
Silencing of long noncoding RNA HOXD-AS1 inhibits proliferation, cell cycle progression, migration and invasion of hepatocellular carcinoma cells through MEK/ERK pathway.
Small GTPase RBJ promotes cancer progression by mobilizing MDSCs via IL-6.
Sodium butyrate improved intestinal immune function associated with NF-?B and p38MAPK signalling pathways in young grass carp (Ctenopharyngodon idella).
Sophocarpine prevents cigarette smoke-induced restenosis in rat carotid arteries after angioplasty.
Sp1 regulates Raf/MEK/ERK-induced p21(CIP1) transcription in TP53-mutated cancer cells.
Specific amino acid deficiency alters the expression of genes in human melanoma and other tumor cell lines.
Steady-State Levels of Phosphorylated Mitogen-Activated Protein Kinase Kinase 1/2 Determined by Mortalin/HSPA9 and Protein Phosphatase 1 Alpha in KRAS and BRAF Tumor Cells.
Structural basis for the action of the drug trametinib at KSR-bound MEK.
Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets.
Structure-guided cancer blockade between bioactive bursehernin and proteins: Molecular docking and molecular dynamics study.
STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis.
Suppression of mitochondrial biogenesis through toll-like receptor 4-dependent mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling in endotoxin-induced acute kidney injury.
Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer.
Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells.
Synthesis and structure-activity relationships of 3-cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) inhibitors.
t10,c12-Conjugated linoleic acid stimulates mammary tumor progression in Her2/ErbB2 mice through activation of both proliferative and survival pathways.
Targeted Therapy in Melanoma and Mechanisms of Resistance.
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model.
Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.
Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.
Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors.
Targeting Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase in the Mutant (V600E) B-Raf Signaling Cascade Effectively Inhibits Melanoma Lung Metastases.
Targets of Raf in tumorigenesis.
The Association of Modifiable Breast Cancer Risk Factors and Somatic Genomic Alterations in Breast Tumors: The Cancer Genome Atlas Network.
The D Domain of LRRC4 anchors ERK1/2 in the cytoplasm and competitively inhibits MEK/ERK activation in glioma cells.
The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-alpha and EGF in human cancer cells.
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib.
The induction of prostaglandin E2 production, interleukin-6 production, cell cycle arrest, and cytotoxicity in primary oral keratinocytes and KB cancer cells by areca nut ingredients is differentially regulated by MEK/ERK activation.
The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation.
The intermediate-activity L597VBRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.
The landscape of candidate driver genes differs between male and female breast cancer.
The long non-coding RNA PVT1/miR-145-5p/ITGB8 axis regulates cell proliferation, apoptosis, migration and invasion in non-small cell lung cancer cells.
The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma.
The MEK/ERK Network as a Therapeutic Target in Human Cancer.
The MEK/ERK pathway acts upstream of NF kappa B1 (p50) homodimer activity and Bcl-2 expression in a murine B-cell lymphoma cell line. MEK inhibition restores radiation-induced apoptosis.
The membrane immunoglobulin receptor utilizes a Shc/Grb2/hSOS complex for activation of the mitogen-activated protein kinase cascade in a B-cell line.
The miR-19b-3p-MAP2K3-STAT3 feedback loop regulates cell proliferation and invasion in esophageal squamous cell carcinoma.
The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
The Similar Effects of miR-512-3p and miR-519a-2-5p on the Promotion of Hepatocellular Carcinoma: Different Tunes Sung With Equal Skill.
The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis.
The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.
TIMP-2 binding with cellular MT1-MMP stimulates invasion-promoting MEK/ERK signaling in cancer cells.
TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy.
TPL2 kinase action and control of inflammation.
Tpl2 promotes neutrophil trafficking, oxidative burst, and bacterial killing.
Transforming growth factor {beta}1-mediated activation of the smooth muscle {alpha}-actin gene in human pulmonary myofibroblasts is inhibited by tumor necrosis factor-{alpha} via mitogen-activated protein kinase kinase 1-dependent Induction of the Egr-1 transcriptional repressor.
Treatment of Advanced Melanoma: Past, Present and Future.
Treatment of Aggressive Thyroid Cancer.
Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.
Truncation- and motif-based pan-cancer analysis reveals tumor-suppressing kinases.
Tuberous sclerosis-associated neoplasms express activated p42/44 mitogen-activated protein (MAP) kinase, and inhibition of MAP kinase signaling results in decreased in vivo tumor growth.
Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma.
Tumor necrosis factor receptor 1/c-Jun-NH2-kinase signaling promotes human neoplasia.
Tumor necrosis factor signaling to stress-activated protein kinase (SAPK)/Jun NH2-terminal kinase (JNK) and p38. Germinal center kinase couples TRAF2 to mitogen-activated protein kinase/ERK kinase kinase 1 and SAPK while receptor interacting protein associates with a mitogen-activated protein kinase kinase kinase upstream of MKK6 and p38.
Tumor necrosis factor-alpha regulates inflammatory and mesenchymal responses via mitogen-activated protein kinase kinase, p38, and nuclear factor kappaB in human endometriotic epithelial cells.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogen-activated protein kinase kinase inhibitors in human leukemia cells that ectopically express Bcl-2 and Bcl-xL.
Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures.
Tumor-Associated Macrophages Suppress the Cytotoxic Activity of Antimitotic Agents.
Tumour necrosis factor alpha and interleukin 1 signalling: do MAPKK kinases connect it all?
UBE2N Promotes Melanoma Growth via MEK/FRA1/SOX10 Signaling.
Unbiased Proteomic and Phosphoproteomic Analysis Identifies Response Signatures and Novel Susceptibilities After Combined MEK and mTOR Inhibition in BRAFV600E Mutant Glioma.
Uncoupling FoxO3A mitochondrial and nuclear functions in cancer cells undergoing metabolic stress and chemotherapy.
Unintentional weakness of cancers: the MEK/ERK pathway as a double-edged sword.
Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways.
Upregulation of lactate dehydrogenase a by 14-3-3? leads to increased glycolysis critical for breast cancer initiation and progression.
Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells.
Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants.
Vinculin negatively regulates transcription of MT1-MMP through MEK/ERK pathway.
Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.
Wogonoside promotes apoptosis and ER stress in human gastric cancer cells by regulating the IRE1? pathway.
Zonula occludens-1 (ZO-1) redistribution is involved in the regulation of cell dissociation in pancreatic cancer cells.
[18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models.
[Angiotensin II and aldosterone stimulate alpha1-(I) procollagen mRNA expression in hepatic stellate cells via activation of ERK1/2 and AP-1]
[Coexpression of MAP2K4 and vimentin proteins in human endometrial carcinoma and its clinicopathological significance].
[Effects of angiotensin II and aldosterone on NF-kappaB binding activity in hepatic stellate cells]
[Future targeting of the RAS/RAF/MEK/ERK signaling pathway in oncology: the example of melanoma].
[MAP kinase module: role in the control of cell proliferation]
[Progress of anti-tumor study based on BRAF].
[Retracted] Anticancer activity of caffeic acid n?butyl ester against A431Ā skin carcinoma cell line occurs via induction of apoptosis and inhibition of the mTOR/PI3K/AKT signaling pathway.
Neoplasms, Germ Cell and Embryonal
Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells.
Neoplastic Cells, Circulating
Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis.
Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells.
Neuralgia
Following nerve injury neuregulin-1 drives microglial proliferation and neuropathic pain via the MEK/ERK pathway.
Neurosteroid Allopregnanolone Suppresses Median Nerve Injury-induced Mechanical Hypersensitivity and Glial Extracellular Signal-regulated Kinase Activation through ?-Aminobutyric Acid Type A Receptor Modulation in the Rat Cuneate Nucleus.
Overexpression of miR-206 ameliorates chronic constriction injury-induced neuropathic pain in rats via the MEK/ERK pathway by targeting brain-derived neurotrophic factor.
Neurilemmoma
Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ.
Inhibition of MEK pathway in vestibular schwannoma cell culture.
Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2.
Neurobehavioral Manifestations
Map2k7 Haploinsufficiency Induces Brain Imaging Endophenotypes and Behavioral Phenotypes Relevant to Schizophrenia.
Neuroblastoma
All-trans retinoic acid induces COX-2 and prostaglandin E2 synthesis in SH-SY5Y human neuroblastoma cells: involvement of retinoic acid receptors and extracellular-regulated kinase 1/2.
Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression.
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Correction: LGR5 regulates pro-survival MEK/ERK and proliferative Wnt/?-catenin signalling in neuroblastoma.
Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.
Effect of retinoic acid and delta-like 1 homologue (DLK1) on differentiation in neuroblastoma.
ERK1/2 is a negative regulator of homeodomain protein Arix/Phox2a.
Genetic alterations in lung adenocarcinoma with a micropapillary component.
Growth Inhibition and Apoptosis of Neuroblastoma Cells Through ROS-Independent MEK/ERK Activation by Sulforaphane.
Histiocytic neoplasms in the era of personalized genomic medicine.
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Immunohistochemical staining of phosphorylated-ERK in post-chemotherapeutic samples is a potential predictor of the prognosis of neuroblastoma.
Induction of cyclin-dependent kinase 5 and its activator p35 through the extracellular-signal-regulated kinase and protein kinase A pathways during retinoic-acid mediated neuronal differentiation in human neuroblastoma SK-N-BE(2)C cells.
Induction of MEK/ERK activity by AZD8055 confers acquired resistance in neuroblastoma.
LGR5 regulates pro-survival MEK/ERK and proliferative Wnt/?-catenin signalling in neuroblastoma.
Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review.
Modulation of extracellular signal-regulated kinase (ERK) by opioid and cannabinoid receptors that are expressed in the same cell.
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.
Phospholipase D2 activation by p38 MAP kinase is involved in neurite outgrowth.
Rapid membrane effects of steroids in neuroblastoma cells: effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription.
The proliferative response of NB69 human neuroblastoma cells to a 50 Hz magnetic field is mediated by ERK1/2 signaling.
The retinoid anticancer signal: mechanisms of target gene regulation.
Neurofibroma, Plexiform
Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens.
The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.
Neurofibromatoses
Heat shock factor 1 (HSF1)-targeted anticancer therapeutics: overview of current preclinical progress.
Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens.
The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.
Neurofibromatosis 1
Heat shock factor 1 (HSF1)-targeted anticancer therapeutics: overview of current preclinical progress.
Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens.
The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.
Newcastle Disease
Newcastle Disease Virus Nonstructural V Protein Upregulates SOCS3 Expression to Facilitate Viral Replication Depending on the MEK/ERK Pathway.
Newcastle Disease Virus V Protein Promotes Viral Replication in HeLa Cells through the Activation of MEK/ERK Signaling.
Noonan Syndrome
Inducible Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Aberrant Extracellular Regulated Kinase 5 and Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Concomitantly Promote Hypertrophic Cardiomyopathy in RAF1-Associated Noonan Syndrome.
Obesity
MAP2K3 is associated with body mass index in American Indians and Caucasians and may mediate hypothalamic inflammation.
MiR-21a-5p suppresses bisphenol A-induced pre-adipocyte differentiation by targeting map2k3 through MKK3/p38/MAPK.
Optic Nerve Injuries
PI3K/akt, JAK/STAT and MEK/ERK pathway inhibition protects retinal ganglion cells via different mechanisms after optic nerve injury.
Osteoarthritis
Egr-1 inhibits the expression of extracellular matrix genes in chondrocytes by TNFalpha-induced MEK/ERK signalling.
In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes.
Inhibition of interleukin-1beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappaB and AP-1: Potential mechanism for Diacerein effects in osteoarthritis.
Rhein inhibits interleukin-1 beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappa B and AP-1 in chondrocytes cultured in hypoxia: a potential mechanism for its disease-modifying effect in osteoarthritis.
Osteoarthritis, Knee
Activation of the extracellular-signal-regulated kinase (ERK)/c-Jun N-terminal kinase (JNK) signal pathway and osteogenic factors in subchondral bone of patients with knee osteoarthritis.
Osteoporosis, Postmenopausal
Disturbed MEK/ERK signaling increases osteoclast activity via the Hedgehog-Gli pathway in postmenopausal osteoporosis.
QingYan formula extracts protect against postmenopausal osteoporosis in ovariectomized rat model via active ER-dependent MEK/ERK and PI3K/Akt signal pathways.
Osteosarcoma
(-)-Epigallocatechin-3-gallate inhibits osteosarcoma cell invasiveness by inhibiting the MEK/ERK signaling pathway in human osteosarcoma cells.
3-Hydroxyflavone inhibits human osteosarcoma U2OS and 143B cells metastasis by affecting EMT and repressing u-PA/MMP-2 via FAK-Src to MEK/ERK and RhoA/MLC2 pathways and reduces 143B tumor growth inĀ vivo.
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.
Association of RDM1 with osteosarcoma progression via cell cycle and MEK/ERK signalling pathway regulation.
ERK1/2 activation mediated by the nutlin?3?induced mitochondrial translocation of p53.
Factors Associated with Promoted Proliferation of Osteosarcoma by Peptidylarginine Deiminase 4.
Hematopoietic cell kinase enhances osteosarcoma development via the MEK/ERK pathway.
Increased expression of ecotropic viral integration site 2A indicates a poor prognosis and promotes osteosarcoma evolution through activating MEK/ERK pathway.
MAPK7 and MAP2K4 as prognostic markers in osteosarcoma.
MicroRNA-27a promotes proliferation, migration and invasion by targeting MAP2K4 in human osteosarcoma cells.
microRNA-363 plays a tumor suppressive role in osteosarcoma by directly targeting MAP2K4.
p16(INK4A) inhibits the pro-metastatic potentials of osteosarcoma cells through targeting the ERK pathway and TGF-?1.
RRAS2 knockdown suppresses osteosarcoma progression by inactivating the MEK/ERK signaling pathway.
Signal transduction pathways involved in the stimulation of tissue type plasminogen activator by interleukin-1alpha and Porphyromonas gingivalis in human osteosarcoma cells.
Specific inhibitor of MEK-mediated cross-talk between ERK and p38 MAPK during differentiation of human osteosarcoma cells.
Targeted MEK inhibition by cobimetinib enhances doxorubicin's efficacy in osteosarcoma models.
Ovarian Neoplasms
Analysis of the mitogen-activated protein kinase kinase 4 (MAP2K4) tumor suppressor gene in ovarian cancer.
Down-regulation of TRIB3 inhibits the progression of ovarian cancer via MEK/ERK signaling pathway.
E-cadherin promotes proliferation of human ovarian cancer cells in vitro via activating MEK/ERK pathway.
Gallic acid sensitizes paclitaxel-resistant human ovarian carcinoma cells through an increase in reactive oxygen species and subsequent downregulation of ERK activation.
Kaempferol exerts anti-proliferative effects on human ovarian cancer cells by inducing apoptosis, G0/G1 cell cycle arrest and modulation of MEK/ERK and STAT3 pathways.
KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine.
LncRNA HOTTIP promotes the proliferation and invasion of ovarian cancer cells by activating the MEK/ERK pathway.
Low-grade epithelial ovarian cancer: a number of distinct clinical entities?
Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway.
MicroRNA-338-3p suppresses ovarian cancer cells growth and metastasis: implication of Wnt/catenin beta and MEK/ERK signaling pathways.
Mitogen-activated Protein Kinase Kinase 6-fusion Protein (MAP2K6-FP) Potentiates the Anti-tumor effects of Paclitaxel in Ovarian Cancer.
Novel functions for 2-phenylbenzimidazole-5-sulphonic acid: Inhibition of ovarian cancer cell responses and tumour angiogenesis.
p21-Activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients.
Propofol suppresses cell viability, cell cycle progression and motility and induces cell apoptosis of ovarian cancer cells through suppressing MEK/ERK signaling via targeting circVPS13C/miR-145 axis.
SPARCL1 suppresses the proliferation and migration of human ovarian cancer cells via the MEK/ERK signaling.
Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells.
Using MKK4's metastasis suppressor function to identify and dissect cancer cell-microenvironment interactions during metastatic colonization.
[Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Overnutrition
A Maternal High-Fat Diet Induces DNA Methylation Changes That Contribute to Glucose Intolerance in Offspring.
Pancreatic Neoplasms
A FAM83A Positive Feed-back Loop Drives Survival and Tumorigenicity of Pancreatic Ductal Adenocarcinomas.
A new prognosis prediction model combining TNM stage with MAP2K4 and JNK in postoperative pancreatic cancer patients.
Analysis of invasion-metastasis mechanism in pancreatic cancer: involvement of tight junction transmembrane protein occludin and MEK/ERK signal transduction pathway in cancer cell dissociation.
Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer.
Arrangement of expression and distribution of tight junction protein claudin-1 in cell dissociation of pancreatic cancer cells.
Benzophenone Compounds, from a Marine-Derived Strain of the Fungus Pestalotiopsis neglecta, Inhibit Proliferation of Pancreatic Cancer Cells by Targeting the MEK/ERK Pathway.
C6orf106 accelerates pancreatic cancer cell invasion and proliferation via activating ERK signaling pathway.
Correction to Benzophenone Compounds, from a Marine-Derived Strain of the Fungus Pestalotiopsis neglecta, Inhibit Proliferation of Pancreatic Cancer Cells by Targeting the MEK/ERK Pathway.
Direct TGF-?1 signaling between activated platelets and pancreatic cancer cells primes cisplatin insensitivity.
Dual PI3K/mTOR inhibitors induce rapid over-activation of the MEK/ERK pathway in human pancreatic cancer cells through suppression of mTORC2.
ERR? promotes pancreatic cancer progression by enhancing the transcription of PAI1 and activating the MEK/ERK pathway.
Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.
Expression of connective tissue growth factor in pancreatic cancer cell lines.
Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis.
Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancer.
Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer.
Involvement of matrix metalloproteinase-7 in invasion-metastasis through induction of cell dissociation in pancreatic cancer.
Involvement of MMP-7 in invasion of pancreatic cancer cells through activation of the EGFR mediated MEK-ERK signal transduction pathway.
Involvement of the mitogen-activated protein kinase kinase 2 in the induction of cell dissociation in pancreatic cancer.
KrasG12D mutation contributes to regulatory T cell conversion through activation of the MEK/ERK pathway in pancreatic cancer.
LIM-only protein FHL2 critically determines survival and radioresistance of pancreatic cancer cells.
LPS Induced miR-181a Promotes Pancreatic Cancer Cell Migration via Targeting PTEN and MAP2K4.
LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways.
MEK Inhibition Potentiates the Activity of Hsp90 Inhibitor 17-AAG against Pancreatic Cancer Cells.
MEK Inhibitor Suppresses Expression of the miR-17-92 Cluster with G1-Phase Arrest in HT-29 Human Colon Cancer Cells and MIA PaCa-2 Pancreatic Cancer Cells.
MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells.
MEK/ERK-mediated proliferation is negatively regulated by P38 map kinase in the human pancreatic cancer cell line, PANC-1.
Multiple signal pathways are involved in the mitogenic effect of 5(S)-HETE in human pancreatic cancer.
Netrin-1 suppresses the MEK/ERK pathway and ITGB4 in pancreatic cancer.
Novel Agents in the Management of Pancreatic Adenocarcinoma: Phase I Studies. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Relationship between activation of epidermal growth factor receptor and cell dissociation in pancreatic cancer.
Synergistic effect between erlotinib and MEK inhibitors in KRAS wildtype human pancreatic cancer cells.
The glucosylceramide synthase inhibitor PDMP sensitizes pancreatic cancer cells to MEK/ERK inhibitor AZD-6244.
The MEK/ERK pathway promotes NOTCH signalling in pancreatic cancer cells.
Zonula occludens-1 (ZO-1) redistribution is involved in the regulation of cell dissociation in pancreatic cancer cells.
Pancreatitis
Mitogen-activated Protein Kinase Kinase Activity Maintains Acinar-to-Ductal Metaplasia and Is Required for Organ Regeneration in Pancreatitis.
Parkinson Disease
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
Neuroprotective properties of icariin in MPTP-induced mouse model of Parkinson's disease: Involvement of PI3K/Akt and MEK/ERK signaling pathways.
Paronychia
Cutaneous drug eruptions associated with the use of new oncological drugs.
Peritoneal Fibrosis
MicroRNA-21 contributes to high glucose-induced fibrosis in peritoneal mesothelial cells in rat models by activation of the Ras-MAPK signaling pathway via Sprouty-1.
Pheochromocytoma
Constitutively active mutant of the mitogen-activated protein kinase kinase MEK1 induces epithelial dedifferentiation and growth inhibition in madin-darby canine kidney-C7 cells.
GDNF-induced leukemia inhibitory factor can mediate differentiation via the MEK/ERK pathway in pheochromocytoma cells derived from nf1-heterozygous knockout mice.
HSP70 inhibitor VER155008 suppresses pheochromocytoma cell and xenograft growth by inhibition of PI3K/AKT/mTOR and MEK/ERK pathways.
Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor.
Signaling pathways for PC12 cell differentiation: making the right connections.
Specific regulation of JNK signalling by the novel rat MKK7gamma1 isoform.
phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase deficiency
Lipid phosphatase SHIP-1 regulates chondrocyte hypertrophy and skeletal development.
Pneumonia
MAPK kinase 3 potentiates Chlamydia HSP60-induced inflammatory response through distinct activation of NF-?B.
Polycystic Kidney Diseases
?-catenin ablation exacerbates polycystic kidney disease progression.
Polycystic Kidney, Autosomal Dominant
Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys.
Polycystic Ovary Syndrome
Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro.
Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway.
Inhibition of the NEDD8 conjugation pathway induces calcium-dependent compensatory activation of the pro-survival MEK/ERK pathway in acute lymphoblastic leukemia.
Mitogen-activated protein kinase is required for bryostatin 1-induced differentiation of the human acute lymphoblastic leukemia cell line Reh.
PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: New options for targeted therapy.
The autophagy induced by curcumin via MEK/ERK pathway plays an early anti-leukemia role in human Philadelphia chromosome-positive acute lymphoblastic leukemia SUP-B15 cells.
The histone demethylase PHF8 promotes adult acute lymphoblastic leukemia through interaction with the MEK/ERK signaling pathway.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors.
Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway.
Inhibition of the MAP2K7-JNK pathway with 5Z-7-oxozeaenol induces apoptosis in T-cell acute lymphoblastic leukemia.
Interleukin-7 in T-cell acute lymphoblastic leukemia: an extrinsic factor supporting leukemogenesis?
KLF4 represses MAP2K7 signaling in T-ALL.
Novel tumor-suppressor function of KLF4 in pediatric T-cell acute lymphoblastic leukemia.
Prostatic Neoplasms
"MKK4 suppresses metastatic colonization by multiple highly metastatic prostate cancer cell lines through a transient impairment in cell cycle progression"
Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression.
Commentary on Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C, Department of Urology, Columbia University College of Physicians and Surgeons, New York, NY.
Counteracting the activation of pAkt by inhibition of MEK/Erk inhibition reduces actin disruption-mediated apoptosis in PTEN-null PC3M prostate cancer cell lines.
Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (review).
Identification of Genes Required for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells In Vitro.
Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen.
Insulin exacerbated high glucose-induced epithelial-mesenchymal transition in prostatic epithelial cells BPH-1 and prostate cancer cells PC-3 via MEK/ERK signaling pathway.
KrĆ¼ppel-like factor 5 promotes apoptosis triggered by tumor necrosis factor ? in LNCaP prostate cancer cells via up-regulation of mitogen-activated protein kinase kinase 7.
Loss of scinderin decreased expression of epidermal growth factor receptor and promoted apoptosis of castration-resistant prostate cancer cells.
Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling.
MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.
MiR-203 over-expression promotes prostate cancer cell apoptosis and reduces ADM resistance.
Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis.
Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers.
Mitogen-Activated Protein Kinase Kinase 4/c-Jun NH2-Terminal Kinase Kinase 1 Protein Expression Is Subject to Translational Regulation in Prostate Cancer Cell Lines.
Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17.
Modeling MEK4 Kinase Inhibitors through Perturbed Electrostatic Potential Charges.
Novel roles for class II Phosphoinositide 3-Kinase C2? in signalling pathways involved in prostate cancer cell invasion.
PAGE4 promotes prostate cancer cells survive under oxidative stress through modulating MAPK/JNK/ERK pathway.
Requirement for direct cross-talk between B1 and B2 kinin receptors for the proliferation of androgen-insensitive prostate cancer PC3 cells.
REX-1 Represses RASSF1a and Activates the MEK/ERK Pathway to Promote Tumorigenesis in Prostate Cancer.
Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
Specific amino acid deficiency alters the expression of genes in human melanoma and other tumor cell lines.
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model.
The PPAR Gamma Agonist Troglitazone Regulates Erk 1/2 Phosphorylation via a PPAR?-Independent, MEK-Dependent Pathway in Human Prostate Cancer Cells.
Transforming growth factor-beta1 (TGF-beta)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-beta-activated kinase 1 and mitogen-activated protein kinase kinase 3.
[Effects of P2Y receptor activation on prostatic cancer cells requiring ERK1/2 or p38 cascade]
[SHP2 and MKP5 in P2Y purinergic receptor-mediated prostate cancer invasion]
Pulmonary Arterial Hypertension
TRPM7 channel inhibition exacerbates pulmonary arterial hypertension through MEK/ERK pathway.
Pulmonary Disease, Chronic Obstructive
Anti-inflammatory action of herbal medicine comprised of Scutellaria baicalensis and Chrysanthemum morifolium.
Dual Role For A MEK Inhibitor As A Modulator Of Inflammation And Host Defense Mechanisms With Potential Therapeutic Application In COPD.
Rare variant of MAP2K7 is associated with increased risk of COPD in southern and eastern Chinese.
Pulmonary Fibrosis
A novel lnc-PCF promotes the proliferation of TGF-?1-activated epithelial cells by targeting miR-344a-5p to regulate map3k11 in pulmonary fibrosis.
Danshensu alleviates bleomycin-induced pulmonary fibrosis by inhibiting lung fibroblast-to-myofibroblast transition via the MEK/ERK signaling pathway.
MEK-ERK Pathway Modulation Ameliorates Pulmonary Fibrosis Associated with Epidermal Growth Factor Receptor Activation.
Purpura
Circulating IgA from acute stage of childhood Henoch-SchƃĀ¶nlein purpura can enhance endothelial interleukin (IL)-8 production through MEK/ERK signalling pathway.
Rectal Neoplasms
MAP kinase genes and colon and rectal cancer.
Renal Insufficiency
?-catenin ablation exacerbates polycystic kidney disease progression.
Reperfusion Injury
Activation of the ERK1/2 pathway by the CaMEK gene via adeno-associated virus serotype 9 in cardiomyocytes.
Evidence that the MEK/ERK but not the PI3K/Akt pathway is required for protection from myocardial ischemia-reperfusion injury by 3',4'-dihydroxyflavonol.
The role of 1,25-dyhydroxyvitamin D3 in mouse liver ischemia reperfusion injury: regulation of autophagy through activation of MEK/ERK signaling and PTEN/PI3K/Akt/mTORC1 signaling.
Restless Legs Syndrome
The effects of a MAP2K5 microRNA target site SNP on risk for anxiety and depressive disorders.
Retinal Vein Occlusion
PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion.
Retinoblastoma
ANRIL acts as onco-lncRNA by regulation of microRNA-24/c-Myc, MEK/ERK and Wnt/?-catenin pathway in retinoblastoma.
Downregulation of CKS1B restrains the proliferation, migration, invasion and angiogenesis of retinoblastoma cells through the MEK/ERK signaling pathway.
Increased expression of FGF1-mediated signaling molecules in adipose tissue of obese mice.
Neurotrophin Receptors TrkA and TrkB in Retinoblastoma Are Differentially Expressed Depending on Cellular Differentiation.
pRb phosphorylation regulates the proliferation of supporting cells in gentamicin-damaged neonatal avian utricle.
ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway.
Retinopathy of Prematurity
Persistent inhibition of oxygen-induced retinal neovascularization by anthrax lethal toxin.
Rhabdomyosarcoma
Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
Genetic and molecular alterations in rhabdomyosarcoma: mRNA overexpression of MCL1 and MAP2K4 genes.
MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals.
p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
Rhabdomyosarcoma, Embryonal
c-Myc Sustains Transformed Phenotype and Promotes Radioresistance of Embryonal Rhabdomyosarcoma Cell Lines.
Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population.
MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma.
MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals.
Sarcoma
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.
Differentially expressed kinase genes associated with trypsinogen activation in rat pancreatic acinar cells treated with taurolithocholic acid 3-sulfate.
ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcathecol (4-NC).
Factors influencing the CNS distribution of a novel MEK-1/2 inhibitor: implications for combination therapy for melanoma brain metastases.
Genetic alterations in lung adenocarcinoma with a micropapillary component.
Histiocytic neoplasms in the era of personalized genomic medicine.
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
lncRNA SLC16A1-AS1 as a novel prognostic biomarker in non-small cell lung cancer.
MEK1/2 inhibitors in the treatment of gynecologic malignancies.
Ocular Changes in Metastatic Melanoma Patients Treated with MEK Inhibitor Cobimetinib and BRAF Inhibitor Vemurafenib.
Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series.
Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report.
Quercetin inhibits migration and invasion of SAS human oral cancer cells through inhibition of NF-?B and matrix metalloproteinase-2/-9 signaling pathways.
Ras/ERK signaling pathway is involved in curcumin-induced cell cycle arrest and apoptosis in human gastric carcinoma AGS cells.
The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases.
Treatment of Advanced Melanoma: Past, Present and Future.
Triiodothyronine stimulates steroid and VEGF production in murine Leydig cells via cAMP-PKA pathway.
Triplet combination of BRAF, MEK and PD-1/PD-L1 blockade in melanoma: the more the better?
Sarcoma, Avian
Molecularly targeted therapy for gastrointestinal cancer.
Sarcoma, Ewing
Erratum: miR-30d inhibits cell biological progression of Ewing's sarcoma by suppressing the MEK/ERK and PI3K/Akt pathways in vitro.
miR-30d inhibits cell biological progression of Ewing's sarcoma by suppressing the MEK/ERK and PI3K/Akt pathways
Scleroderma, Systemic
Erratum to: Thrombospondin 1 is a key mediator of transforming growth factor b-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanism.
Thrombospondin 1 is a key mediator of transforming growth factor beta-mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanism.
Seizures
Formation of a tumour necrosis factor receptor 1 molecular scaffolding complex and activation of apoptosis signal-regulating kinase 1 during seizure-induced neuronal death.
The JNK inhibitor D-JNKI-1 blocks apoptotic JNK signaling in brain mitochondria.
Sepsis
Endothelial MKK3 is a critical mediator of lethal murine endotoxemia and acute lung injury.
Phosphorylation of Extracellular Signal-Regulated Kinase (ERK)-1/2 Is Associated with the Downregulation of Peroxisome Proliferator-Activated Receptor (PPAR)-? during Polymicrobial Sepsis.
Skin Neoplasms
3-Deoxysappanchalcone Inhibits Skin Cancer Proliferation by Regulating T-Lymphokine-Activated Killer Cell-Originated Protein Kinase in vitro and in vivo.
The mitogen-activated protein kinase kinase 4 has a pro-oncogenic role in skin cancer.
Sleep Deprivation
Influence of sleep deprivation on expression of MKK4 and c-fos in the mandibular condylar cartilage of rats.
Small Cell Lung Carcinoma
Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Spinal Cord Injuries
Age-dependent autophagy induction after injury promotes axon regeneration by limiting NOTCH.
An injectable, self-healing, electroconductive extracellular matrix-based hydrogel for enhancing tissue repair after traumatic spinal cord injury.
Type I Interferon Inhibits Astrocytic Gliosis and Promotes Functional Recovery after Spinal Cord Injury by Deactivation of the MEK/ERK Pathway.
Squamous Cell Carcinoma of Head and Neck
Development and validation of a novel survival model for head and neck squamous cell carcinoma based on autophagy-related genes.
Fibroblast growth factor receptor 3-mediated reactivation of ERK signaling promotes head and neck squamous cancer cell insensitivity to MEK inhibition.
Kinin b2 receptor mediates induction of cyclooxygenase-2 and is overexpressed in head and neck squamous cell carcinomas.
MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Overexpression of integrin ?v facilitates proliferation and invasion of oral squamous cell carcinoma cells via MEK/ERK signaling pathway that is activated by interaction of integrin ?v?8 with type ? collagen.
Overexpression of mitogen-activated protein kinase kinase 4 and nuclear factor-kappaB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis.
Regulation of cisplatin-resistant head and neck squamous cell carcinoma by the SRC/ETS-1 signaling pathway.
[The relationship between expression of mitogen-activated protein kinase kinase 4 and metastasis in oral squamous cell carcinoma].
Starvation
A Caenorhabditis elegans MAP kinase kinase, MEK-1, is involved in stress responses.
A phosphatidylinositol 3-kinase inhibitor induces a senescent-like growth arrest in human diploid fibroblasts.
Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy.
Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis.
LIN-35/Rb causes starvation-induced germ cell apoptosis via CED-9/Bcl2 downregulation in Caenorhabditis elegans.
Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells.
Onset of gluconate-H+ symport in Schizosaccharomyces pombe is regulated by the kinases Wis1 and Pka1, and requires the gti1+ gene product.
PI3K/Akt and MAPK pathways evoke activation of FoxO transcription factor to undergo neuronal apoptosis in brain of the silkworm Bombyx mori (Lepidoptera: Bombycidae).
The fission yeast stress-responsive MAPK pathway promotes meiosis via the phosphorylation of Pol II CTD in response to environmental and feedback cues.
Status Epilepticus
Peroxisome Proliferator-Activated Receptor ? Coactivator 1? Activates Vascular Endothelial Growth Factor That Protects Against Neuronal Cell Death Following Status Epilepticus through PI3K/AKT and MEK/ERK Signaling.
Stomach Diseases
Helicobacter pylori cytotoxin-associated gene A protein upregulates ?-enolase expression via Src/MEK/ERK pathway: implication for progression of gastric cancer.
Stomach Neoplasms
ALOX5-5-HETE promotes gastric cancer growth and alleviates chemotherapy toxicity via MEK/ERK activation.
Bone morphogenetic protein 2 mediates epithelial-mesenchymal transition via AKT and ERK signaling pathways in gastric cancer.
Cellular prion protein promotes invasion and metastasis of gastric cancer.
Dynamic reprogramming of signaling upon met inhibition reveals a mechanism of drug resistance in gastric cancer.
ERK inhibition enhances TSA-induced gastric cancer cell apoptosis via NF-?B-dependent and Notch-independent mechanism.
Exosomes Released by Gastric Cancer Cells Induce Transition of Pericytes Into Cancer-Associated Fibroblasts.
GĀ protein subunit ? q regulates gastric cancer growth via the p53/p21 and MEK/ERK pathways.
Helicobacter pylori induces Snail expression through ROS-mediated activation of Erk and inactivation of GSK-3? in human gastric cancer cells.
Human gastrin mRNA expression up-regulated by Helicobacter pylori CagA through MEK/ERK and JAK2-signaling pathways in gastric cancer cells.
Hyperactivation of MEK/ERK pathway by Ca2+ /calmodulin-dependent protein kinase kinase 2Ā promotes cellular proliferation by activating cyclin-dependent kinasesĀ and minichromosome maintenance proteinĀ in gastric cancer cells.
Increased expression of mitogen-activated protein kinase and its upstream regulating signal in human gastric cancer.
Inhibition of MEK blocks GRP78 up-regulation and enhances apoptosis induced by ER stress in gastric cancer cells.
LAMC1 is related to the poor prognosis of patients with gastric cancer and facilitates cancer cell malignancies.
Low expression of SPARC in gastric cancer-associated fibroblasts leads to stemness transformation and 5-fluorouracil resistance in gastric cancer.
miR-199a Regulates the Tumor Suppressor Mitogen-Activated Protein Kinase Kinase Kinase 11 in Gastric Cancer.
Pro-apoptotic role of the MEK/ERK pathway in ursodeoxycholic acid-induced apoptosis in SNU601 gastric cancer cells.
Regulation of hepatocyte growth factor-mediated urokinase plasminogen activator secretion by MEK/ERK activation in human stomach cancer cell lines.
Silibinin suppresses TNF-alpha-induced MMP-9 expression in gastric cancer cells through inhibition of the MAPK pathway.
Stromal interaction molecule 1 plays an important role in gastric cancer progression.
The tumor promoting roles of HSP60 and HIF2? in gastric cancer cells.
Truncation- and motif-based pan-cancer analysis reveals tumor-suppressing kinases.
Stroke
Activation of neuronal Ras-related C3 botulinum toxin substrate 1 (Rac1) improves post-stroke recovery and axonal plasticity in mice.
Combination treatment with U0126 and rt-PA prevents adverse effects of the delayed rt-PA treatment after acute ischemic stroke.
Ras-Related C3 Botulinum Toxin Substrate 1 Promotes Axonal Regeneration after Stroke in Mice.
Subarachnoid Hemorrhage
Blockade of the MEK/ERK pathway with a raf inhibitor prevents activation of pro-inflammatory mediators in cerebral arteries and reduction in cerebral blood flow after subarachnoid hemorrhage in a rat model.
Improvement in neurological outcome and abolition of cerebrovascular endothelin B and 5-hydroxytryptamine 1B receptor upregulation through mitogen-activated protein kinase kinase 1/2 inhibition after subarachnoid hemorrhage in rats.
Tachycardia
Cilostazol Prevents Atrial Structural Remodeling through the MEK/ERK Pathway in a Canine Model of Atrial Tachycardia.
Tetanus
C-terminal fragment of tetanus toxin heavy chain activates Akt and MEK/ERK signalling pathways in a Trk receptor-dependent manner in cultured cortical neurons.
Thanatophoric Dysplasia
C-type natriuretic Peptide plasma levels are elevated in subjects with achondroplasia, hypochondroplasia, and thanatophoric dysplasia.
Thymoma
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Distinct roles for p42/p44 and p38 mitogen-activated protein kinases in the induction of IL-2 by IL-1.
Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells.
Effects of phorbol ester on mitogen-activated protein kinase kinase activity in wild-type and phorbol ester-resistant EL4 thymoma cells.
PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.
Protein phosphatase 3 differentially modulates vascular endothelial growth factor- and fibroblast growth factor 2-stimulated cell proliferation and signaling in ovine fetoplacental artery endothelial cells.
The Anti-Melanogenesis Effect of 3,4-Dihydroxybenzalacetone through Downregulation of Melanosome Maturation and Transportation in B16F10 and Human Epidermal Melanocytes.
Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways.
Thyroid Cancer, Papillary
Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Dual specificity phosphatase 6 as a predictor of invasiveness in papillary thyroid cancer.
Leptin enhances migration of human papillary thyroid cancer cells through the PI3K/AKT and MEK/ERK signaling pathways.
Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer.
Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells.
Thyroid Carcinoma, Anaplastic
Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer.
Thyroid Neoplasms
BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.
Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.
Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.
Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies.
Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways.
Toxemia
Highly predictive support vector machine (SVM) models for anthrax toxin lethal factor (LF) inhibitors.
Toxic Optic Neuropathy
Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series.
PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion.
Triple Negative Breast Neoplasms
DHEA inhibits proliferation, migration and alters mesenchymal-epithelial transition proteins through the PI3K/Akt pathway in MDA-MB-231 cells.
High expression of MKK3 is associated with worse clinical outcomes in African American breast cancer patients.
Metalloprotease-dependent activation of EGFR modulates CD44(+)/CD24(-) populations in triple negative breast cancer cells through the MEK/ERK pathway.
Methylation-dependent MCM6 repression induced by LINC00472 inhibits triple-negative breast cancer metastasis by disturbing the MEK/ERK signaling pathway.
miR-125b inhibited epithelial-mesenchymal transition of triple-negative breast cancer by targeting MAP2K7.
Tuberculosis
Mitogen-activated protein kinases mediate Mycobacterium tuberculosis-induced CD44 surface expression in monocytes.
Mitogen-activated protein kinases mediate the production of B-cell lymphoma 2 protein by Mycobacterium tuberculosis in monocytes.
Mycobacterium tuberculosis H37Rv induces monocytic release of interleukin-6 via activation of mitogen-activated protein kinases: inhibition by N-acetyl-L-cysteine.
Role of mitogen-activated protein kinase pathways in the production of tumor necrosis factor-alpha, interleukin-10, and monocyte chemotactic protein-1 by Mycobacterium tuberculosis H37Rv-infected human monocytes.
Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells with MEK/ERK Signaling Pathway Inhibitors.
Tuberous Sclerosis
A non-canonical MEK/ERK signaling pathway regulates autophagy via regulating Beclin 1.
A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
Urinary Bladder Neoplasms
Inhibition of TPL2 by interferon-? suppresses bladder cancer through activation of PDE4D.
MEK1 and MEK2 differentially regulate human insulin- and insulin glargine-induced human bladder cancer T24 cell proliferation.
Stress-activated kinase pathway alteration is a frequent event in bladder cancer.
The tumor-suppressor gene Nkx2.8 suppresses bladder cancer proliferation through upregulation of FOXO3a and inhibition of the MEK/ERK signaling pathway.
Uterine Cervical Neoplasms
Carvacrol induces cytotoxicity in human cervical cancer cells but causes cisplatin resistance: Involvement of MEK-ERK activation.
LncRNA SNHG20 promotes cell proliferation and invasion via miR-140-5p-ADAM10 axis in cervical cancer.
RACK1 promotes the invasive activities and lymph node metastasis of cervical cancer via galectin-1.
SLP-2 inhibits cisplatin-induced apoptosis through MEK/ERK signaling and mitochondrial apoptosis pathway in cervical cancer cells.
The Association Between -1304T>G Polymorphism in the Promoter of Mitogen-Activated Protein Kinase Kinase 4 Gene and the Risk of Cervical Cancer in Chinese Population.
Vaccinia
A mitogenic signal triggered at an early stage of vaccinia virus infection: implication of MEK/ERK and protein kinase A in virus multiplication.
c-Jun integrates signals from both MEK/ERK and MKK/JNK pathways upon vaccinia virus infection.
Viral exploitation of the MEK/ERK pathway - A tale of vaccinia virus and other viruses.
Vascular System Injuries
In vivo gene transfer: prevention of neointima formation by inhibition of mitogen-activated protein kinase kinase.
Virus Diseases
A mitogenic signal triggered at an early stage of vaccinia virus infection: implication of MEK/ERK and protein kinase A in virus multiplication.
c-Jun integrates signals from both MEK/ERK and MKK/JNK pathways upon vaccinia virus infection.
Investigation on the partial resistance of Cpkk2 knock out strain of Cryphonectria parasitica to Cryphonectria hypovirus 1 infection in presence of Geneticin and Geneticin resistance gene.
Isolation and expression analysis of an MAPKK gene from Fenneropenaeus chinensis in response to white spot syndrome virus infection.
Vitamin E Deficiency
Vitamin E deficiency impairs the somatostatinergic receptor-effector system and leads to phosphotyrosine phosphatase overactivation and cell death in the rat hippocampus.
Whooping Cough
A neuroactive steroid inhibits guinea pig airway sensory nerves via Maxi-K channel activation.
A role of protein kinase C mu in signalling from the human adenosine A1 receptor to the nucleus.
Activation of rat frizzled-1 promotes Wnt signaling and differentiation of mouse F9 teratocarcinoma cells via pathways that require Galpha(q) and Galpha(o) function.
Alpha2-adrenoceptors in opossum kidney cells couple to stimulation of mitogen-activated protein kinase independently of adenylyl cyclase inhibition.
beta-Migrating very low density lipoprotein (beta VLDL) activates smooth muscle cell mitogen-activated protein (MAP) kinase via G protein-coupled receptor-mediated transactivation of the epidermal growth factor (EGF) receptor: effect of MAP kinase activation on beta VLDL plus EGF-induced cell proliferation.
Biphasic modulation of intracellular Ca2+ concentration by interleukin-1beta in cortical synaptosomes: involvement of a pertussis toxin-sensitive G-protein and mitogen-activated protein kinase.
Conjugated linoleic acid induces human adipocyte delipidation: autocrine/paracrine regulation of MEK/ERK signaling by adipocytokines.
Coupling of serotonin 5-HT1B receptors to activation of mitogen-activated protein kinase (ERK-2) and p70 S6 kinase signaling systems.
Dual mechanisms for lysophospholipid induction of proliferation of human breast carcinoma cells.
Functional coupling of SSTR4, a major hippocampal somatostatin receptor, to adenylate cyclase inhibition, arachidonate release and activation of the mitogen-activated protein kinase cascade.
Human adenosine A1 receptor and P2Y2-purinoceptor-mediated activation of the mitogen-activated protein kinase cascade in transfected CHO cells.
Human Salivary Histatin-1 Promotes Osteogenic Cell Spreading on Both Bio-Inert Substrates and Titanium SLA Surfaces.
Idiopathic pulmonary fibrosis fibroblasts migrate and proliferate to CC chemokine ligand 21.
Molecular effects of proinsulin C-peptide.
Nerve growth factor stimulation of p42/p44 mitogen-activated protein kinase in PC12 cells: role of G(i/o), G protein-coupled receptor kinase 2, beta-arrestin I, and endocytic processing.
P2Y receptor-mediated inhibition of tumor necrosis factor alpha -stimulated stress-activated protein kinase activity in EAhy926 endothelial cells.
PAR1 and PAR2 couple to overlapping and distinct sets of G proteins and linked signaling pathways to differentially regulate cell physiology.
Plasmin induces smooth muscle cell proliferation.
Prosaptide activates the MAPK pathway by a G-protein-dependent mechanism essential for enhanced sulfatide synthesis by Schwann cells.
Prostaglandin D2 induces the production of human beta-defensin-3 in human keratinocytes.
Regulation of p42/p44 mitogen-activated protein kinase by the human adenosine A3 receptor in transfected CHO cells.
Regulation of Ras.GTP loading and Ras-Raf association in neonatal rat ventricular myocytes by G protein-coupled receptor agonists and phorbol ester. Activation of the extracellular signal-regulated kinase cascade by phorbol ester is mediated by Ras.
Stimulation of mitogen activated protein kinase by LDL and oxLDL in human U-937 macrophage-like cells.
The beta1-adrenergic receptor mediates extracellular signal-regulated kinase activation via Galphas.
The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells.
Xaliproden (SR57746A) induces 5-HT1A receptor-mediated MAP kinase activation in PC12 cells.
Wiskott-Aldrich Syndrome
Gene expression pattern in human brain endothelial cells in response to Neisseria meningitidis.
Yellow Fever
MEK/ERK activation plays a decisive role in yellow fever virus replication: implication as an antiviral therapeutic target.
The small molecule AZD6244 inhibits dengue virus replication in vitro and protects against lethal challenge in a mouse model.